Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Mateo, J., Lord, C.J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S.B. & de Bono, J.S., et al. (2019). A decade of clinical development of PARP inhibitors in perspective. Annals of oncology, Vol.30 (9), pp. 1437-1447.  show abstract

Moss, C.A., Cojocaru, E., Hanwell, J., Ward, S., Xu, W., van Zyl, M., O'Leary, L., de Bono, J.S., Banerji, U., Kaye, S.B., et al. (2019). Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. European journal of cancer, Vol.114, pp. 97-106.

Jones, R.L., Ratain, M.J., O'Dwyer, P.J., Siu, L.L., Jassem, J., Medioni, J., DeJonge, M., Rudin, C., Sawyer, M., Khayat, D., et al. (2019). Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European journal of cancer, Vol.120, pp. 132-139.

Gaspar, N., Marshall, L.V., Binner, D., Herold, R., Rousseau, R., Blanc, P., Capdeville, R., Carleer, J., Copland, C., Kerloeguen, Y., et al. (2018). Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE. Annals of oncology, Vol.29 (3), pp. 766-771.

Ameratunga, M., Chénard-Poirier, M., Moreno Candilejo, I., Pedregal, M., Lui, A., Dolling, D., Aversa, C., Ingles Garces, A., Ang, J.E., Banerji, U., et al. (2018). Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. European journal of cancer, Vol.89, pp. 56-63.

Sundar, R., Custodio, A., Petruckevich, A., Chénard-Poirier, M., Ameratunga, M., Collins, D., Lim, J., Kaye, S.B., Tunariu, N., Banerji, U., et al. (2018). Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical oncology, Vol.30 (3), pp. 185-191.

Oza, A., Kaye, S., Van Tornout, J., Sessa, C., Gore, M., Naumann, R.W., Hirte, H., Colombo, N., Chen, J., Gorla, S., et al. (2018). Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic oncology, Vol.149 (2), pp. 275-282.

Sundar, R., McVeigh, T., Dolling, D., Petruckevitch, A., Diamantis, N., Ang, J.E., Chenard-Poiriér, M., Collins, D., Lim, J., Ameratunga, M., et al. (2018). Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. European journal of cancer, Vol.101, pp. 55-61.

Ingles Garces, A.H., Fontes Dias, M.S., Bizzo, S., Paulino, E., Ferreira Moreira, C.G., Kaye, S., Santos Thuler, L.C. & de Melo, A.C. (2018). Prevalence and risk factors of HBV, HCV, and HIV infections among cervical cancer patients. European journal of gynaecological oncology, Vol.39 (4), pp. 585-589.

Lheureux, S., Lai, Z., Dougherty, B.A., Runswick, S., Hodgson, D.R., Timms, K.M., Lanchbury, J.S., Kaye, S., Gourley, C., Bowtell, D., et al. (2017). Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. Clinical cancer research, Vol.23 (15), pp. 4086-4094.

McLachlan, J., Boussios, S., Okines, A., Glaessgen, D., Bodlar, S., Kalaitzaki, R., Taylor, A., Lalondrelle, S., Gore, M., Kaye, S., et al. (2017). The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. Clinical oncology, Vol.29 (3), pp. 153-160.

Dougherty, B.A., Lai, Z., Hodgson, D.R., Orr, M.C., Hawryluk, M., Sun, J., Yelensky, R., Spencer, S.K., Robertson, J.D., Ho, T.W., et al. (2017). Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget, Vol.8 (27).

George, A., Banerjee, S. & Kaye, S. (2017). Olaparib and somatic BRCA mutations. Oncotarget, Vol.8 (27).

Dolly, S.O., Migali, C., Tunariu, N., Della-Pepa, C., Khakoo, S., Hazell, S., de Bono, J.S., Kaye, S.B. & Banerjee, S. (2017). Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. Esmo open, Vol.2 (1), pp. e000101-e000101.

George, A., Kristeleit, R., Rafii, S., Michie, C.O., Bowen, R., Michalarea, V., van Hagen, T., Wong, M., Rallis, G., Molife, L.R., et al. (2017). Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. European journal of cancer, Vol.76, pp. 52-59.

George, A., Kaye, S. & Banerjee, S. (2017). Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature reviews clinical oncology, Vol.14 (5), pp. 284-296.

de Bono, J., Ramanathan, R.K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D.C., et al. (2017). Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer discovery, Vol.7 (6), pp. 620-629.

Capelan, M., Roda, D., Geuna, E., Rihawi, K., Bodla, S., Kaye, S.B., Bhosle, J., Banerji, U., O’Brien, M., de Bono, J.S., et al. (2017). Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung cancer, Vol.111, pp. 6-11.

Ang, J.E., Pal, A., Asad, Y.J., Henley, A.T., Valenti, M., Box, G., de haven Brandon, A., Revell, V.L., Skene, D.J., Venturi, M., et al. (2017). Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Molecular cancer therapeutics, Vol.16 (10), pp. 2315-2323.

George, A., McLachlan, J., Tunariu, N., Della Pepa, C., Migali, C., Gore, M., Kaye, S. & Banerjee, S. (2017). The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. Bmc cancer, Vol.17 (1).

Rafii, S., Gourley, C., Kumar, R., Geuna, E., Ang, J.E., Rye, T., Chen, L.-., Shapira-Frommer, R., Friedlander, M., Matulonis, U., et al. (2017). Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget, Vol.8 (29).

Perez-Lopez, R., Roda, D., Jimenez, B., Brown, J., Mateo, J., Carreira, S., Lopez, J., Banerji, U., Molife, L.R., Koh, D.-., et al. (2017). High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget, Vol.8 (61).

Heath, O.M., van Beekhuizen, H.J., Nama, V., Kolomainen, D., Nobbenhuis, M.A., Ind, T.E., Sohaib, S.A., Lofts, F.J., Heenan, S., Gore, M., et al. (2016). Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases. Thrombosis research, Vol.137, pp. 30-35.

Khan, K.H., Yap, T.A., Ring, A., Molife, L.R., Bodla, S., Thomas, K., Zivi, A., Smith, A., Judson, I., Banerji, U., et al. (2016). Phase I trial outcomes in older patients with advanced solid tumours. British journal of cancer, Vol.114 (3), pp. 262-268.

Brown, J.S., Kaye, S.B. & Yap, T.A. (2016). PARP inhibitors: the race is on. British journal of cancer, Vol.114 (7), pp. 713-715.

Ledermann, J.A., Embleton, A.C., Raja, F., Perren, T.J., Jayson, G.C., Rustin, G.J., Kaye, S.B., Hirte, H., Eisenhauer, E., Vaughan, M., et al. (2016). Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. The lancet, Vol.387 (10023), pp. 1066-1074.

Mateo, J., Olmos, D., Dumez, H., Poondru, S., Samberg, N.L., Barr, S., Van Tornout, J.M., Jie, F., Sandhu, S., Tan, D.S., et al. (2016). A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. British journal of cancer, Vol.114 (8), pp. 889-896.

Kaye, S.B. (2016). Progress in the treatment of ovarian cancer—lessons from homologous recombination deficiency—the first 10 years. Annals of oncology, Vol.27 (suppl 1), pp. i1-i3.

Matulonis, U.A., Penson, R.T., Domchek, S.M., Kaufman, B., Shapira-Frommer, R., Audeh, M.W., Kaye, S., Molife, L.R., Gelmon, K.A., Robertson, J.D., et al. (2016). Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety. Annals of oncology, Vol.27 (6), pp. 1013-1019.

Mateo, J., Moreno, V., Gupta, A., Kaye, S.B., Dean, E., Middleton, M.R., Friedlander, M., Gourley, C., Plummer, R., Rustin, G., et al. (2016). An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. Targeted oncology, Vol.11 (3), pp. 401-415.

Ang, J.E., Pandher, R., Ang, J.C., Asad, Y.J., Henley, A.T., Valenti, M., Box, G., de Haven Brandon, A., Baird, R.D., Friedman, L., et al. (2016). Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Molecular cancer therapeutics, Vol.15 (6), pp. 1412-1424.

Moschetta, M., George, A., Kaye, S.B. & Banerjee, S. (2016). BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Annals of oncology, Vol.27 (8), pp. 1449-1455.

Monk, B.J., Lorusso, D., Italiano, A., Kaye, S.B., Aracil, M., Tanović, A. & D’Incalci, M. (2016). Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer treatment reviews, Vol.50, pp. 175-182.

Dolly, S.O., Kalaitzaki, E., Puglisi, M., Stimpson, S., Hanwell, J., Fandos, S.S., Stapleton, S., Ansari, T., Peckitt, C., Kaye, S., et al. (2016). A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer, Vol.122 (22), pp. 3501-3508.

Bhattacharya, B., Low, S.H., Chong, M.L., Chia, D., Koh, K.X., Sapari, N.S., Kaye, S., Hung, H., Benoukraf, T. & Soong, R., et al. (2016). Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer. Oncotarget, Vol.7 (20).

Wilson, M.K., Collyar, D., Chingos, D.T., Friedlander, M., Ho, T.W., Karakasis, K., Kaye, S., Parmar, M.K., Sydes, M.R., Tannock, I.F., et al. (2015). Outcomes and endpoints in cancer trials: bridging the divide. The lancet oncology, Vol.16 (1), pp. e43-e52.

Sarker, D., Ang, J.E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P.A., Raynaud, F.I., Levy, G., Ware, J.A., et al. (2015). First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. Clinical cancer research, Vol.21 (1), pp. 77-86.

Kumar, R., Geuna, E., Michalarea, V., Guardascione, M., Naumann, U., Lorente, D., Kaye, S.B. & de Bono, J.S. (2015). The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials. British journal of cancer, Vol.112 (7), pp. 1157-1165.

Tan, D.S. & Kaye, S.B. (2015). Chemotherapy for Patients with BRCA1 and BRCA2–Mutated Ovarian Cancer: Same or Different?. American society of clinical oncology educational book, (35), pp. 114-121.

Heath, O., van Beekhuizen, H., Kolomainen, D., Nama, V., Nobbenhuis, M., Ind, T., Sohaib, A., Lofts, F., Heenan, S., Gore, M., et al. (2015). SYMPTOMATIC AND ASYMPTOMATIC VENOUS THROMBOEMBOLISM AT TIME OF DIAGNOSIS OF PRIMARY OVARIAN CANCER. International journal of gynecological cancer, Vol.25 (9), pp. 387-387.

Kolomainen, D.F., Butler, J., Barton, D.P., Ind, T.E., Nobbenhuis, M.A., Lalondrelle, S., Taylor, A., Shepherd, J.H., Gore, M.E., Kaye, S.B., et al. (2015). IS THERE A SURVIVAL BENEFIT FOR PATIENTS WHO RECEIVE POST-OPERATIVE ADJUVANT CHEMOTHERAPY FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY (SCRS) FOR RECURRENT EPITHELIAL OVARIAN CANCER (EOC)?. International journal of gynecological cancer, Vol.25 (9), pp. 1407-1407.

Lima, J., Mclachlan, J., della Peppa, C., Nobbenhuis, M., Gore, M., Kaye, S. & Banerjee, S. (2015). CLINICAL OUTCOMES OF LOW GRADE SEROUS OVARIAN CARCINOMA: A TWENTY FIVE YEAR RETROSPECTIVE CASE SERIES OF THE ROYAL MARSDEN EXPERIENCE. International journal of gynecological cancer, Vol.25 (9), pp. 1420-1421.

Younger, E., Okines, A.F., Tan, D.S., Anandappa, G., Tokaca, N., Thomas, B., Gore, M., Kaye, S. & Banerjee, S. (2015). CARBOPLATIN DESENSITISATION EXPERIENCE IN CLINICAL PRACTICE. International journal of gynecological cancer, Vol.25 (9), pp. 508-508.

Seifert, H., Georgiou, A., Alexander, H., McLachlan, J., Bodla, S., Kaye, S., Barton, D., Nobbenhuis, M., Gore, M. & Banerjee, S., et al. (2015). Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC). Gynecologic oncology, Vol.139 (2), pp. 216-220.

Seifert, H., Georgiou, A., Alexander, H., McLachlan, J., Bodla, S., Kaye, S., Barton, D., Nobbenhuis, M., Gore, M. & Banerjee, S., et al. (2015). Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC). Gynecologic oncology, Vol.139 (2), pp. 216-220.

Geuna, E., Roda, D., Rafii, S., Jimenez, B., Capelan, M., Rihawi, K., Montemurro, F., Yap, T.A., Kaye, S.B., De Bono, J.S., et al. (2015). Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. British journal of cancer, Vol.113 (11), pp. 1541-1547.

Jones, R.L., Kim, E.S., Nava-Parada, P., Alam, S., Johnson, F.M., Stephens, A.W., Simantov, R., Poondru, S., Gedrich, R., Lippman, S.M., et al. (2015). Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors. Clinical cancer research, Vol.21 (4), pp. 693-700.

Rafii, S., Roda, D., Geuna, E., Jimenez, B., Rihawi, K., Capelan, M., Yap, T.A., Molife, L.R., Kaye, S.B., de Bono, J.S., et al. (2015). Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clinical cancer research, Vol.21 (8), pp. 1869-1876.

Cassier, P.A., Polivka, V., Judson, I., Soria, J.-., Penel, N., Marsoni, S., Verweij, J., Schellens, J.H., Morales-Barrera, R., Schöffski, P., et al. (2014). Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. Annals of oncology, Vol.25 (6), pp. 1222-1228.

Fotopoulou, C., Vergote, I., Mainwaring, P., Bidzinski, M., Vermorken, J.B., Ghamande, S.A., Harnett, P., Del Prete, S.A., Green, J.A., Spaczynski, M., et al. (2014). Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Annals of oncology, Vol.25 (1), pp. 160-165.

Monk, B.J., Kaye, S.B., Poveda, A., Herzog, T.J., Aracil, M., Nieto, A., Badri, N., Parekh, T.V., Tanović, A. & Galmarini, C.M., et al. (2014). Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. Gynecologic oncology, Vol.132 (1), pp. 176-180.

Charbonneau, B., Block, M.S., Bamlet, W.R., Vierkant, R.A., Kalli, K.R., Fogarty, Z., Rider, D.N., Sellers, T.A., Tworoger, S.S., Poole, E., et al. (2014). Risk of Ovarian Cancer and the NF- B Pathway: Genetic Association with IL1A and TNFSF10. Cancer research, Vol.74 (3), pp. 852-861.

Charbonneau, B., Moysich, K.B., Kalli, K.R., Oberg, A.L., Vierkant, R.A., Fogarty, Z.C., Block, M.S., Maurer, M.J., Goergen, K.M., Fridley, B.L., et al. (2014). Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. Cancer immunology research, Vol.2 (4), pp. 332-340.

McNeish, I.A., Ledermann, J.A., Webber, L., James, L., Kaye, S.B., Hall, M., Hall, G., Clamp, A., Earl, H., Banerjee, S., et al. (2014). A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Annals of oncology, Vol.25 (10), pp. 1988-1995.

Block, M.S., Charbonneau, B., Vierkant, R.A., Fogarty, Z., Bamlet, W.R., Pharoah, P.D., Rossing, M.A., Cramer, D., Pearce, C.L., Schildkraut, J., et al. (2014). Variation in NF- B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer epidemiology biomarkers & prevention, Vol.23 (7), pp. 1421-1427.

Glasspool, R.M., Brown, R., Gore, M.E., Rustin, G.J., McNeish, I.A., Wilson, R.H., Pledge, S., Paul, J., Mackean, M., Hall, G.D., et al. (2014). A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British journal of cancer, Vol.110 (8), pp. 1923-1929.

Syrios, J., Banerjee, S. & Kaye, S.B. (2014). Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets - Where Are we Now?. Anticancer research, Vol.34 (5), pp. 2069-2077.

Postel-Vinay, S., Collette, L., Paoletti, X., Rizzo, E., Massard, C., Olmos, D., Fowst, C., Levy, B., Mancini, P., Lacombe, D., et al. (2014). Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. European journal of cancer, Vol.50 (12), pp. 2040-2049.

Paoletti, X., Le Tourneau, C., Verweij, J., Siu, L.L., Seymour, L., Postel-Vinay, S., Collette, L., Rizzo, E., Ivy, P., Olmos, D., et al. (2014). Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. European journal of cancer, Vol.50 (12), pp. 2050-2056.

Canario, R., Lima, J.P., Migali, C., Tunariu, N., George, A., Kaye, S.B., Gore, M.E. & Banerjee, S. (2014). 877PDCLINICAL OUTCOMES OF RECURRENT OVARIAN GRANULOSA CELL TUMOURS TREATED WITH LETROZOLE: A 10-YEAR RETROSPECTIVE CASE-SERIES OF THE ROYAL MARSDEN HOSPITAL. Annals of oncology, Vol.25 (suppl_4), pp. iv305-iv306.

Khan, K., Ang, J.E., Starling, N., Sclafani, F., Shah, K., Judson, I., Molife, L.R., Banerji, U., de Bono, J.S., Cunningham, D., et al. (2014). Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric cancer, Vol.17 (4), pp. 621-629.

Lheureux, S., Ledermann, J., Kaye, S., Gourley, C., Friedlander, M., Bowtell, D., De Greve, J., DeFazio, A., Frommer, R., De Bono, J.S., et al. (2014). A PILOT INTEGRATED ANALYSIS OF LONG-TERM BENEFIT OF OLAPARIB IN OVARIAN CANCER: RESULTS OF FEASIBILITY TESTING. International journal of gynecological cancer, Vol.24 (9), pp. 141-142.

Moreno Garcia, V., Olmos, D., Gomez-Roca, C., Cassier, P.A., Morales-Barrera, R., Del Conte, G., Gallerani, E., Brunetto, A.T., Schoffski, P., Marsoni, S., et al. (2014). Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical cancer research, Vol.20 (22), pp. 5663-5671.

Kaye, S.B., Poole, C.J., Dańska-Bidzińska, A., Gianni, L., Del Conte, G., Gorbunova, V., Novikova, E., Strauss, A., Moczko, M., McNally, V.A., et al. (2013). A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann oncol, Vol.24 (1), pp. 145-152.  show abstract

Attard, G. & Kaye, S.B. (2013). Identifying prognostic signatures in the blood of ovarian cancer patients. Gynecol oncol, Vol.128 (1), pp. 1-2.

Kaye, S.B., Poole, C.J., Danska-Bidzinska, A., Gianni, L., Del Conte, G., Gorbunova, V., Novikova, E., Strauss, A., Moczko, M., McNally, V.A., et al. (2013). A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Annals of oncology, Vol.24 (1), pp. 145-152.

Ang, J.E., Gourley, C., Powell, C.B., High, H., Shapira-Frommer, R., Castonguay, V., De Greve, J., Atkinson, T., Yap, T.A., Sandhu, S., et al. (2013). Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin cancer res, Vol.19 (19), pp. 5485-5493.  show abstract

Banerjee, S. & Kaye, S.B. (2013). New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin cancer res, Vol.19 (5), pp. 961-968.  show abstract

Barber, L.J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D.N., Reis Filho, J.S., Moreno, V., et al. (2013). Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J pathol, Vol.229 (3), pp. 422-429.  show abstract

Banerjee, S., Rustin, G., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., et al. (2013). A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann oncol, Vol.24 (3), pp. 679-687.  show abstract

Maria del Campo, J., Sessa, C., Krasner, C.N., Vermorken, J.B., Colombo, N., Kaye, S., Gore, M., Zintl, P., Gomez, J., Parekh, T., et al. (2013). Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Medical oncology, Vol.30 (1).

Permuth-Wey, J., Lawrenson, K., Shen, H.C., Velkova, A., Tyrer, J.P., Chen, Z., Lin, H.-., Chen, Y.A., Tsai, Y.-., Qu, X., et al. (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21 31. Nature communications, Vol.4.

Tan, D.S., Yap, T.A., Hutka, M., Roxburgh, P., Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E. & Kaye, S.B., et al. (2013). Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur j cancer, Vol.49 (6), pp. 1246-1253.  show abstract

Kipps, E., Tan, D.S. & Kaye, S.B. (2013). Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat rev cancer, Vol.13 (4), pp. 273-282.  show abstract

Hall, M., Gourley, C., McNeish, I., Ledermann, J., Gore, M., Jayson, G., Perren, T., Rustin, G. & Kaye, S. (2013). Targeted anti-vascular therapies for ovarian cancer: current evidence. Br j cancer, Vol.108 (2), pp. 250-258.  show abstract

Sandhu, S.K., Omlin, A., Hylands, L., Miranda, S., Barber, L.J., Riisnaes, R., Reid, A.H., Attard, G., Chen, L., Kozarewa, I., et al. (2013). Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann oncol, Vol.24 (5), pp. 1416-1418.

White, K.L., Vierkant, R.A., Fogarty, Z.C., Charbonneau, B., Block, M.S., Pharoah, P.D., Chenevix-Trench, G., Rossing, M.A., Cramer, D.W., Pearce, C.L., et al. (2013). Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer epidemiology biomarkers & prevention, Vol.22 (5), pp. 987-992.

Singh, S., Kaye, S., Francis, N., Peston, D., Gore, M., McClure, M. & Bunker, C. (2013). Human endogenous retrovirus K (HERV-K) rec mRNA is expressed in primary melanoma but not in benign naevi or normal skin. Pigment cell & melanoma research, Vol.26 (3), pp. 426-428.

Sandhu, S.K., Schelman, W.R., Wilding, G., Moreno, V., Baird, R.D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013). The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet oncol, Vol.14 (9), pp. 882-892.  show abstract

Yap, T.A., Arkenau, H.-., Camidge, D.R., George, S., Serkova, N.J., Gwyther, S.J., Spratlin, J.L., Lal, R., Spicer, J., Desouza, N.M., et al. (2013). First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin cancer res, Vol.19 (4), pp. 909-919.  show abstract

Tan, D.S., Miller, R.E. & Kaye, S.B. (2013). New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br j cancer, Vol.108 (8), pp. 1553-1559.  show abstract

Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B.Y., Amnon, A., Bell-McGuinn, K.M., Chen, L.-., Friedlander, M., et al. (2012). Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J clin oncol, Vol.30 (4), pp. 372-379.  show abstract

Kaye, S.B., Fehrenbacher, L., Holloway, R., Amit, A., Karlan, B., Slomovitz, B., Sabbatini, P., Fu, L., Yauch, R.L., Chang, I., et al. (2012). A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin cancer res, Vol.18 (23), pp. 6509-6518.  show abstract

Olmos, D., Ang, J.E., Gomez-Roca, C., Morales-Barrera, R., Vulink, A.J., Massard, C., Kaye, S. & EDDN, (2012). Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al : a new, simple and objective prognostic score for phase I cancer patients. Eur j cancer, Vol.48 (4), pp. 594-596.

Vidal, L., Magem, M., Barlow, C., Pardo, B., Florez, A., Montes, A., Garcia, M., Judson, I., Lebedinsky, C., Kaye, S.B., et al. (2012). Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Invest new drugs, Vol.30 (2), pp. 616-628.  show abstract

Kolomainen, D.F., Daponte, A., Barton, D.P., Pennert, K., Ind, T.E., Bridges, J.E., Shepherd, J.H., Gore, M.E., Kaye, S.B. & Riley, J., et al. (2012). Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol oncol, Vol.125 (1), pp. 31-36.  show abstract

Carden, C.P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M.D., Clarke, P.A., et al. (2012). The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol cancer ther, Vol.11 (7), pp. 1609-1617.  show abstract

Molife, L.R., Alam, S., Olmos, D., Puglisi, M., Shah, K., Fehrmann, R., Trani, L., Tjokrowidjaja, A., de Bono, J.S., Banerji, U., et al. (2012). Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann oncol, Vol.23 (8), pp. 1968-1973.  show abstract

Krasner, C.N., Poveda, A., Herzog, T.J., Vermorken, J.B., Kaye, S.B., Nieto, A., Lardelli Claret, P., Park, Y.C., Parekh, T. & Monk, B.J., et al. (2012). Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone. Gynecologic oncology, Vol.127 (1), pp. 161-167.

Monk, B.J., Herzog, T.J., Kaye, S.B., Krasner, C.N., Vermorken, J.B., Muggia, F.M., Pujade-Lauraine, E., Park, Y.C., Parekh, T.V. & Poveda, A.M., et al. (2012). Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis. European journal of cancer, Vol.48 (15), pp. 2361-2368.

Messiou, C., Orton, M., Ang, J.E., Collins, D.J., Morgan, V.A., Mears, D., Castellano, I., Papadatos-Pastos, D., Brunetto, A., Tunariu, N., et al. (2012). Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. Radiology, Vol.265 (2), pp. 426-436.  show abstract

Ang, J.E., Kaye, S. & Banerji, U. (2012). Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. Curr drug targets, Vol.13 (12), pp. 1525-1534.  show abstract

Banerjee, S. & Kaye, S. (2012). Progression-free survival versus overall survival in ovarian cancer: where are we now?. Curr oncol rep, Vol.14 (6), pp. 483-485.

Tunariu, N., Kaye, S.B. & Desouza, N.M. (2012). Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?. Br j cancer, Vol.106 (4), pp. 619-628.  show abstract

Moreno Garcia, V., Basu, B., Molife, L.R. & Kaye, S.B. (2012). Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin cancer res, Vol.18 (14), pp. 3750-3761.  show abstract

Olmos, D., A'hern, R.P., Marsoni, S., Morales, R., Gomez-Roca, C., Verweij, J., Voest, E.E., Schöffski, P., Ang, J.E., Penel, N., et al. (2012). Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J clin oncol, Vol.30 (9), pp. 996-1004.  show abstract

Moreno Garcia, V., Thavasu, P., Blanco Codesido, M., Molife, L.R., Vitfell Pedersen, J., Puglisi, M., Basu, B., Shah, K., Iqbal, J., de Bono, J.S., et al. (2012). Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. Br j cancer, Vol.107 (11), pp. 1797-1800.  show abstract

Olmos, D., A'Hern, R.P., Marsoni, S., Morales, R., Gomez-Roca, C., Verweij, J., Voest, E.E., Schoeffski, P., Ang, J.E., Penel, N., et al. (2012). Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. Journal of clinical oncology, Vol.30 (9), pp. 996-1004.

Kaye, S., Aamdal, S., Jones, R., Freyer, G., Pujade-Lauraine, E., de Vries, E.G., Barriuso, J., Sandhu, S., Tan, D.S., Hartog, V., et al. (2012). Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br j cancer, Vol.106 (11), pp. 1728-1734.  show abstract

Naing, A., Aghajanian, C., Raymond, E., Olmos, D., Schwartz, G., Oelmann, E., Grinsted, L., Burke, W., Taylor, R., Kaye, S., et al. (2012). Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br j cancer, Vol.107 (7), pp. 1093-1099.  show abstract

Ploquin, A., Olmos, D., Lacombe, D., A'Hern, R., Duhamel, A., Twelves, C., Marsoni, S., Morales-Barrera, R., Soria, J.-., Verweij, J., et al. (2012). Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. British journal of cancer, Vol.107 (7), pp. 1025-1030.

Banerjee, S. & Kaye, S.B. (2012). Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?. Nat rev clin oncol, Vol.9 (4), pp. 194-196.

Vitfell-Pedersen, J., Yap, T.A., Moreno, V., Baird, R.D., Khan, A.Z., Barton, D.P. & Kaye, S.B. (2012). The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials. European journal of gynaecological oncology, Vol.33 (2), pp. 211-213.

Basu, B., Vitfell-Pedersen, J., Moreno Garcia, V., Puglisi, M., Tjokrowidjaja, A., Shah, K., Malvankar, S., Anghan, B., de Bono, J.S., Kaye, S.B., et al. (2012). Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials. Oncology, Vol.83 (4), pp. 177-182.  show abstract

Perkins, G., Yap, T.A., Pope, L., Cassidy, A.M., Dukes, J.P., Riisnaes, R., Massard, C., Cassier, P.A., Miranda, S., Clark, J., et al. (2012). Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. Plos one, Vol.7 (11), p. e47020.  show abstract

Kaye, S.B., Colombo, N., Monk, B.J., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Vergote, I., et al. (2011). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann oncol, Vol.22 (1), pp. 49-58.  show abstract

Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S.B., Colombo, N., et al. (2011). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann oncol, Vol.22 (1), pp. 39-48.  show abstract

Yap, T.A., Olmos, D., Brunetto, A.T., Tunariu, N., Barriuso, J., Riisnaes, R., Pope, L., Clark, J., Futreal, A., Germuska, M., et al. (2011). Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J clin oncol, Vol.29 (10), pp. 1271-1279.  show abstract

Suwaki, N., Vanhecke, E., Atkins, K.M., Graf, M., Swabey, K., Huang, P., Schraml, P., Moch, H., Cassidy, A.M., Brewer, D., et al. (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci transl med, Vol.3 (85), p. 85ra47.  show abstract

Pharoah, P.D., Palmieri, R.T., Ramus, S.J., Gayther, S.A., Andrulis, I.L., Anton-Culver, H., Antonenkova, N., Antoniou, A.C., Goldgar, D., BCFR Investigators, , et al. (2011). The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin cancer res, Vol.17 (11), pp. 3742-3750.  show abstract

Postel-Vinay, S., Gomez-Roca, C., Molife, L.R., Anghan, B., Levy, A., Judson, I., De Bono, J., Soria, J.C., Kaye, S. & Paoletti, X., et al. (2011). Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. J clin oncol, Vol.29 (13), pp. 1728-1735.  show abstract

Rizzo, S., Hersey, J.M., Mellor, P., Dai, W., Santos-Silva, A., Liber, D., Luk, L., Titley, I., Carden, C.P., Box, G., et al. (2011). Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2. Mol cancer ther, Vol.10 (2), pp. 325-335.  show abstract

Rustin, G., Reed, N., Jayson, G.C., Ledermann, J.A., Adams, M., Perren, T., Poole, C., Lind, M., Persic, M., Essapen, S., et al. (2011). A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann oncol, .  show abstract

Stewart, R.M., Wiehlmann, L., Ashelford, K.E., Preston, S.J., Frimmersdorf, E., Campbell, B.J., Neal, T.J., Hall, N., Tuft, S., Kaye, S.B., et al. (2011). Genetic characterization indicates that a specific subpopulation of Pseudomonas aeruginosa is associated with keratitis infections. J clin microbiol, Vol.49 (3), pp. 993-1003.  show abstract

Dedes, K.J., Wetterskog, D., Ashworth, A., Kaye, S.B. & Reis-Filho, J.S. (2011). Emerging therapeutic targets in endometrial cancer. Nat rev clin oncol, Vol.8 (5), pp. 261-271.  show abstract

Forster, M.D., Dedes, K.J., Sandhu, S., Frentzas, S., Kristeleit, R., Ashworth, A., Poole, C.J., Weigelt, B., Kaye, S.B. & Molife, L.R., et al. (2011). Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat rev clin oncol, Vol.8 (5), pp. 302-306.  show abstract

Pacey, S., Ratain, M.J., Flaherty, K.T., Kaye, S.B., Cupit, L., Rowinsky, E.K., Xia, C., O'Dwyer, P.J. & Judson, I.R. (2011). Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest new drugs, Vol.29 (3), pp. 481-488.  show abstract

Jones, R.L., Olmos, D., Thway, K., Fisher, C., Tunariu, N., Postel-Vinay, S., Scurr, M., de Bono, J., Kaye, S.B. & Judson, I.R., et al. (2011). Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer chemother pharmacol, Vol.68 (2), pp. 423-429.  show abstract

Poveda, A., Kaye, S.B., McCormack, R., Wang, S.B., Parekh, T., Ricci, D., Lebedinsky, C.A., Tercero, J.C., Zintl, P. & Monk, B.J., et al. (2011). Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol oncol, Vol.122 (3), pp. 567-572.  show abstract

Banerjee, S. & Kaye, S. (2011). The role of targeted therapy in ovarian cancer. Eur j cancer, Vol.47 Suppl 3, pp. S116-S130.  show abstract

Rudman, S.M., Josephs, D.H., Cambrook, H., Karagiannis, P., Gilbert, A.E., Dodev, T., Hunt, J., Koers, A., Montes, A., Taams, L., et al. (2011). Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin exp allergy, Vol.41 (10), pp. 1400-1413.  show abstract

Kyriazi, S., Collins, D.J., Messiou, C., Pennert, K., Davidson, R.L., Giles, S.L., Kaye, S.B. & Desouza, N.M. (2011). Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients. Radiology, Vol.261 (1), pp. 182-192.  show abstract

Vaughan, S., Coward, J.I., Bast, R.C., Berchuck, A., Berek, J.S., Brenton, J.D., Coukos, G., Crum, C.C., Drapkin, R., Etemadmoghadam, D., et al. (2011). Rethinking ovarian cancer: recommendations for improving outcomes. Nat rev cancer, Vol.11 (10), pp. 719-725.  show abstract

Banerjee, S. & Kaye, S. (2011). PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr oncol rep, Vol.13 (6), pp. 442-449.  show abstract

Tan, D.S., Iravani, M., McCluggage, W.G., Lambros, M.B., Milanezi, F., Mackay, A., Gourley, C., Geyer, F.C., Vatcheva, R., Millar, J., et al. (2011). Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin cancer res, Vol.17 (6), pp. 1521-1534.  show abstract

Ledermann, J.A., Hackshaw, A., Kaye, S., Jayson, G., Gabra, H., McNeish, I., Earl, H., Perren, T., Gore, M., Persic, M., et al. (2011). Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. J clin oncol, .  show abstract

Olmos, D., Baird, R.D., Yap, T.A., Massard, C., Pope, L., Sandhu, S.K., Attard, G., Dukes, J., Papadatos-Pastos, D., Grainger, P., et al. (2011). Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. Clin cancer res, .  show abstract

Amankwah, E.K., Wang, Q.G., Schildkraut, J.M., Tsai, Y.Y., Ramus, S.J., Fridley, B.L., Beesley, J., Johnatty, S.E., Webb, P.M., Chenevix-Trench, G., et al. (2011). Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. Plos one, Vol.6 (5),  show abstract

Kyriazi, S., Collins, D.J., Messiou, C., Pennert, K., Davidson, R.L., Giles, S.L., Kaye, S.B. & deSouza, N.M. (2011). Assessing Chemotherapy Response of Metastatic Ovarian and Primary Peritoneal Cancer with Diffusion-Weighted Magnetic Resonance Imaging: Value of Histogram Analysis of Apparent Diffusion Coefficients. Radiology 2011 (in press), .  show abstract

Brunetto, A., Olmos, D., Arkenau, H.-., Tan, D., Yap, T., de Bono, J., Barriuso, J. & Kaye, S. (2011). Perceptions and referral trends into phase I oncology trials: results of a clinical survey. J oncol, Vol.2011, p. 861401.  show abstract

Papadatos-Pastos, D., Dedes, K.J., de Bono, J.S. & Kaye, S.B. (2011). Revisiting the role of antiandrogen strategies in ovarian cancer. Oncologist, Vol.16 (10), pp. 1413-1421.  show abstract

Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B., Amnon, A., Bell-McGuinn, K.M., Chen, L.-., Friedlander, M., et al. (2011). A phase II, open-label, randomized, multicenter study to compare the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J clin oncol, .

Monk, B.J., Herzog, T.J., Kaye, S.B., Krasner, C.N., Vermorken, J.B., Muggia, F.M., Pujade-Lauraine, E., Lisyanskaya, A.S., Makhson, A.N., Rolski, J., et al. (2010). Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. J clin oncol, Vol.28 (19), pp. 3107-3114.  show abstract

Banerji, U., Camidge, D.R., Verheul, H.M., Agarwal, R., Sarker, D., Kaye, S.B., Desar, I.M., Timmer-Bonte, J.N., Eckhardt, S.G., Lewis, K.D., et al. (2010). The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin cancer res, Vol.16 (5), pp. 1613-1623.  show abstract

Yap, T.A., de Bono, J.S., Kaye, S.B., Tutt, A., Ashworth, A. & Schellens, J.H. (2010). Reply to J Veeck et al. J clin oncol, .

Carden, C.P., Sarker, D., Postel-Vinay, S., Yap, T.A., Attard, G., Banerji, U., Garrett, M.D., Thomas, G.V., Workman, P., Kaye, S.B., et al. (2010). Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug discov today, Vol.15 (3-4), pp. 88-97.  show abstract

Han, L., Kristeleit, R., van Hagen, T., Yap, T., Olmos, D., Carden, C. & Kaye, S. (2010). Characterizing the experience of gynecologic oncology patients in phase 1 studies. Gynecol oncol, Vol.116 (3), pp. S59-S60.

Han, L., Aamdal, S., Boven, E., Freyer, G., Kristensen, G., Jones, R., Pujade-Lauraine, E., De Vries, L., Prahladan, M. & Kaye, S., et al. (2010). Treatment profile of saracatinib (AZD0530) in combination with chemotherapy in patients with advanced ovarian carcinoma. Gynecol oncol, Vol.116 (3), pp. S60-S60.

Han, L.Y., Kipps, E. & Kaye, S.B. (2010). Current treatment and clinical trials in ovarian cancer. Expert opin investig drugs, Vol.19 (4), pp. 521-534.  show abstract

Han, L.Y., Karavasilis, V., Hagen, T., Nicum, S., Thomas, K., Harrison, M., Papadopoulos, P., Blake, P., Barton, D.P., Gore, M., et al. (2010). Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur j cancer, Vol.46 (8), pp. 1359-1364.  show abstract

Vidot, S., Witham, J., Agarwal, R., Greenhough, S., Bamrah, H.S., Tigyi, G.J., Kaye, S.B. & Richardson, A. (2010). Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell signal, Vol.22 (6), pp. 926-935.  show abstract

Kyriazi, S., Kaye, S.B. & deSouza, N.M. (2010). Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nat rev clin oncol, Vol.7 (7), pp. 381-393.  show abstract

Agarwal, R., Gourley, C., Perren, T.J., Reed, N., Parkin, D.E., Carty, K., Rustin, G.J., Gabra, H., Paul, J., Gore, M.E., et al. (2010). First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series. Eur j cancer, Vol.46 (11), pp. 2020-2026.  show abstract

Carden, C.P., Yap, T.A. & Kaye, S.B. (2010). PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr opin oncol, Vol.22 (5), pp. 473-480.  show abstract

Banerjee, S., Kaye, S.B. & Ashworth, A. (2010). Making the best of PARP inhibitors in ovarian cancer. Nat rev clin oncol, Vol.7 (9), pp. 508-519.  show abstract

Baird, R.D., Tan, D.S. & Kaye, S.B. (2010). Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat rev clin oncol, Vol.7 (10), pp. 575-582.  show abstract

Bolton, E.L., Tyrer, J., Song, H., Ramus, S.J., Notaridou, M., Jones, C., Sher, T., Gentry-Maharaj, A., Wozniak, E., Tsai, Y.Y., et al. (2010). Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat genet, Vol.42 (10), pp. 880-+.  show abstract

Brunetto, A.T., Ang, J.E., Olmos, D., Tan, D., Barriuso, J., Arkenau, H.-., Yap, T.A., Molife, L.R., Banerji, U., de Bono, J., et al. (2010). A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition. Eur j cancer, Vol.46 (15), pp. 2739-2745.  show abstract

Trimble, E.L., Birrer, M.J., Hoskins, W.J., Marth, C., Petryshyn, R., Quinn, M., Thomas, G.M., Kitchener, H.C., Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee, , Aghajanian, C., et al. (2010). Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int j gynecol cancer, Vol.20 (7), pp. 1290-1298.  show abstract

Powell, C., Mikropoulos, C., Kaye, S.B., Nutting, C.M., Bhide, S.A., Newbold, K. & Harrington, K.J. (2010). Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer treat rev, Vol.36 (7), pp. 566-575.  show abstract

Kim, E.S., Puzanov, I., Buck, E., Gedrich, R., Poondru, S., Carden, C., Kaye, S.B., Davies, A., Nava-Parada, P. & Miglarese, M.R., et al. (2010). Activity of the IGF1-R/IR Inhibitor OSI-906 in Non-small Cell Lung Cancer (NSCLC): Pre-Clinical and Early Clinical Experience. J thorac oncol, Vol.5 (12), pp. S543-S543.

Gourley, C., Michie, C.O., Roxburgh, P., Yap, T.A., Harden, S., Paul, J., Ragupathy, K., Todd, R., Petty, R., Reed, N., et al. (2010). Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype. J clin oncol, Vol.28 (15), pp. 2505-2511.  show abstract

Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010). Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J clin oncol, Vol.28 (15), pp. 2512-2519.  show abstract

Brunetto, A.T., Sarker, D., Papadatos-Pastos, D., Fehrmann, R., Kaye, S.B., Johnston, S., Allen, M., De Bono, J.S. & Swanton, C. (2010). A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. Br j cancer, Vol.103 (5), pp. 607-612.  show abstract

Kyriazi, S., Nye, E., Stamp, G., Collins, D.J., Kaye, S.B. & deSouza, N.M. (2010). Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy: correlation of apparent diffusion coefficients with epithelial and stromal densities on histology. Cancer biomark, Vol.7 (4), pp. 201-210.  show abstract

Attard, G., Swennenhuis, J.F., Olmos, D., Reid, A.H., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009). Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer res, Vol.69 (7), pp. 2912-2918.  show abstract

Tan, D.S., Lambros, M.B., Rayter, S., Natrajan, R., Vatcheva, R., Gao, Q., Marchio, C., Geyer, F.C., Savage, K., Parry, S., et al. (2009). PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas. Clin cancer res, Vol.15 (7), pp. 2269-2280.  show abstract

Arkenau, H.-., Barriuso, J., Olmos, D., Ang, J.E., de Bono, J., Judson, I. & Kaye, S. (2009). Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J clin oncol, Vol.27 (16), pp. 2692-2696.  show abstract

ten Bokkel Huinink, W., Sufliarsky, J., Smit, W.M., Spanik, S., Wagnerova, M., Hirte, H.W., Kaye, S., Johri, A.R. & Oza, A.M. (2009). Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study. J clin oncol, Vol.27 (19), pp. 3097-3103.  show abstract

Carden, C.P., Banerji, U., Kaye, S.B., Workman, P. & de Bono, J.S. (2009). From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin pharmacol ther, Vol.85 (2), pp. 131-133.  show abstract

Yap, T.A., Carden, C.P. & Kaye, S.B. (2009). Beyond chemotherapy: targeted therapies in ovarian cancer. Nat rev cancer, Vol.9 (3), pp. 167-181.  show abstract

Singh, S., Kaye, S., Francis, N.D., Peston, D., Gore, M.E., McClure, M.O. & Bunker, C.B. (2009). Revisiting the past: utilizing archival tissue for the detection and quantification of gene expression. Brit j dermatol, Vol.160 (4), pp. 885-886.

Graham, J.S., Kaye, S.B. & Brown, R. (2009). The promises and pitfalls of epigenetic therapies in solid tumours. Eur j cancer, Vol.45 (7), pp. 1129-1136.  show abstract

Postel-Vinay, S., Arkenau, H.-., Olmos, D., Ang, J., Barriuso, J., Ashley, S., Banerji, U., De-Bono, J., Judson, I. & Kaye, S., et al. (2009). Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?. Br j cancer, Vol.100 (9), pp. 1373-1378.  show abstract

Baird, R.D., Kitzen, J., Clarke, P.A., Planting, A., Reade, S., Reid, A., Welsh, L., López Lázaro, L., de las Heras, B., Judson, I.R., et al. (2009). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol cancer ther, Vol.8 (6), pp. 1430-1437.  show abstract

Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M.J., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N engl j med, Vol.361 (2), pp. 123-134.  show abstract

Tan, D.S., Thomas, G.V., Garrett, M.D., Banerji, U., de Bono, J.S., Kaye, S.B. & Workman, P. (2009). Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer j, Vol.15 (5), pp. 406-420.  show abstract

Vergote, I., Finkler, N., del Campo, J., Lohr, A., Hunter, J., Matei, D., Kavanagh, J., Vermorken, J.B., Meng, L., Jones, M., et al. (2009). Phase 3 randomised study of canfosfamide (Telcyta (R), TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur j cancer, Vol.45 (13), pp. 2324-2332.  show abstract

Attard, G., Reid, A.H., A'Hern, R., Parker, C., Oommen, N.B., Folkerd, E., Messiou, C., Molife, L.R., Maier, G., Thompson, E., et al. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J clin oncol, Vol.27 (23), pp. 3742-3748.  show abstract

Ang, J.E., Shah, R.N., Everard, M., Keyzor, C., Coombes, I., Jenkins, A., Thomas, K., A'Hern, R., Jones, R.L., Blake, P., et al. (2009). A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Ann oncol, Vol.20 (11), pp. 1787-1793.  show abstract

Singh, S., Kaye, S., Gore, M.E., McClure, M.O. & Bunker, C.B. (2009). The role of human endogenous retroviruses in melanoma. Brit j dermatol, Vol.161 (6), pp. 1225-1231.  show abstract

Yap, T.A., Kaye, S.B. & de Bono, J.S. (2009). Inhibition of Poly(ADP-Ribose) Polymerase in BRCA Mutation Carriers REPLY. New engl j med, Vol.361 (17), pp. 1707-1708.

Arkenau, H.-., Brunetto, A.T., Barriuso, J., Olmos, D., Eaton, D., de Bono, J., Judson, I. & Kaye, S. (2009). Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology, Vol.76 (3), pp. 151-156.  show abstract

Attard, G., Reid, A.H., Yap, T.A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J clin oncol, Vol.26 (28), pp. 4563-4571.  show abstract

Witham, J., Vidot, S., Agarwal, R., Kaye, S.B. & Richardson, A. (2008). Transient ectopic expression as a method to detect genes conferring drug resistance. Int j cancer, Vol.122 (11), pp. 2641-2645.  show abstract

Kaye, S.B. (2008). Reversal of drug resistance in ovarian cancer: Where do we go from here?. J clin oncol, Vol.26 (16), pp. 2616-2618.

Tan, D.S., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., Norman, A., Kaye, S.B. & Gore, M.E., et al. (2008). "BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations. J clin oncol, Vol.26 (34), pp. 5530-5536.  show abstract

Kaye, S.B. (2008). New drugs for ovarian cancer. Clin adv hematol oncol, Vol.6 (2), pp. 91-93.

Linch, M., Stavridi, F., Hook, J., Barbachano, Y., Gore, M. & Kaye, S.B. (2008). Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecol oncol, Vol.109 (1), pp. 27-32.  show abstract

Barrett, S.V., Paul, J., Hay, A., Vasey, P.A., Kaye, S.B., Glasspool, R.M. & Scottish Gynaecological Cancer Tri, (2008). Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann oncol, Vol.19 (5), pp. 898-902.  show abstract

Karavasilis, V., Digue, L., Arkenau, T., Eaton, D., Stapleton, S., de Bono, J., Judson, I. & Kaye, S. (2008). Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital. Eur j cancer, Vol.44 (7), pp. 978-982.  show abstract

Bishara, S., Griffin, M., Cargill, A., Bali, A., Gore, M.E., Kaye, S.B., Shepherd, J.H. & Van Trappen, P.O. (2008). Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur j obstet gynecol reprod biol, Vol.138 (1), pp. 71-75.  show abstract

Richardson, A. & Kaye, S.B. (2008). Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr mol pharmacol, Vol.1 (3), pp. 244-254.  show abstract

Olmos, D., Arkenau, H.T., Ang, J.E., de Bono, J.S., Judson, I. & Kaye, S.B. (2008). Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience. Brit j cancer, Vol.99 (8), pp. 1365-1365.

Banerji, U., de Bono, J., Judson, I., Kaye, S. & Workman, P. (2008). Biomarkers in early clinical trials: the committed and the skeptics. Clin cancer res, Vol.14 (8), p. 2512.

de Bono, J.S., Kristeleit, R., Tolcher, A., Fong, P., Pacey, S., Karavasilis, V., Mita, M., Shaw, H., Workman, P., Kaye, S., et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin cancer res, Vol.14 (20), pp. 6663-6673.  show abstract

Arkenau, H.T., Olmos, D., Ang, J.E., de Bono, J., Judson, I. & Kaye, S. (2008). Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Brit j cancer, Vol.98 (6), pp. 1029-1033.  show abstract

Postel-Vinay, S.C., Arkenau, H., Ashley, S., Barriuso, J., Olmos, D., Shaw, H., Wright, M., Judson, I., De-Bono, J. & Kaye, S.B., et al. (2008). Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter?. Journal of clinical oncology, Vol.26 (15).

Lal, R., Camidge, D.R., George, S., Demetri, G.D., Eckhardt, S.G., Stephens, A., Chick, J., Boinpally, R., Kaye, S.B. & Scurr, M., et al. (2008). A phase I, dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930, an oral tyrosine kinase inhibitor (TKI), in patients (pts) with advanced solid tumors. Journal of clinical oncology, Vol.26 (15).

Ang, J., Arkenau, H., Olmos, D., Barriuso, J., Ashley, S., Little, A., Pacey, S., De Bono, J.S., Judson, I. & Kaye, S.B., et al. (2008). 90-day mortality rate in cancer patients treated within the context of phase I trials: Can we identify patients who should not go on trial?. Journal of clinical oncology, Vol.26 (15).

Tan, D.S., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., Norman, A., Kaye, S.B. & Gore, M.E., et al. (2008). The "BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 1/2 mutations. Journal of clinical oncology, Vol.26 (15).

Arkenau, H., Barriuso, J., Olmos, D., Barlow, C., De Bono, J.S., Judson, I., Stapelton, S., Hanwell, J., Ashley, S. & Kaye, S.B., et al. (2008). Prospective validation of a prognostic score to improve patient selection for phase I trials. Journal of clinical oncology, Vol.26 (15).

Karavasilis, V., Thomas, K., Harrison, M., Papadopoulos, P., Barton, D., Gore, M.E. & Kaye, S.B. (2008). Prognostic value of the rate of rise of CA 125 after first line chemotherapy for survival in patients with relapsed ovarian cancer. Journal of clinical oncology, Vol.26 (15).

Fong, P.C., Boss, D.S., Carden, C.P., Roelvink, M., De Greve, J., Gourley, C.M., Carmichael, J., De Bono, J.S., Schellens, J.H. & Kaye, S.B., et al. (2008). AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Journal of clinical oncology, Vol.26 (15).

Vasey, P.A., Gore, M., Wilson, R., Rustin, G., Gabra, H., Guastalla, J.P., Lauraine, E.P., Paul, J., Carty, K., Kaye, S., et al. (2008). A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Brit j cancer, Vol.98 (11), pp. 1774-1780.  show abstract

Tan, D.S., Ang, J.E. & Kaye, S.B. (2008). Ovarian cancer: can we reverse drug resistance?. Adv exp med biol, Vol.622, pp. 153-167.

Witham, J., Valenti, M.R., De-Haven-Brandon, A.K., Vidot, S., Eccles, S.A., Kaye, S.B. & Richardson, A. (2007). The Bcl-2/Bcl-X-L family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin cancer res, Vol.13 (23), pp. 7191-7198.  show abstract

Molife, R., Fong, P., Scurr, M., Judson, I., Kaye, S. & de Bono, J. (2007). HDAC inhibitors and cardiac safety. Clin cancer res, Vol.13 (3), pp. 1068-1068.

Tan, D.S. & Kaye, S. (2007). Ovarian clear cell adenocarcinoma: a continuing enigma. J clin pathol, Vol.60 (4), pp. 355-360.  show abstract

England, R.A., deSouza, N.M. & Kaye, S.B. (2007). Gliomatosis peritonei: MRI appearances and its potential role in follow up. Br j radiol, Vol.80 (953), pp. e101-e104.  show abstract

Larkin, J.M. & Kaye, S.B. (2007). Potential clinical applications of epothilones: a review of phase II studies. Ann oncol, Vol.18 Suppl 5, pp. v28-v34.  show abstract

Martin, L.-., Head, J.E., Pancholi, S., Salter, J., Quinn, E., Detre, S., Kaye, S., Howes, A., Dowsett, M. & Johnston, S.R., et al. (2007). The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol cancer ther, Vol.6 (9), pp. 2458-2467.  show abstract

Harrison, M.L., Gore, M.E., Spriggs, D., Kaye, S., Iasonos, A., Hensley, M., Aghajanian, C., Venkatraman, E. & Sabbatini, P. (2007). Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol oncol, Vol.106 (3), pp. 469-475.  show abstract

Forster, M.D., Ormerod, M.G., Agarwal, R., Kaye, S.B. & Jackman, A.L. (2007). Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells. Cytom part a, Vol.71A (11), pp. 945-950.  show abstract

de Wit, R., Sleijfer, S., Kaye, S.B., Horwich, A., Mead, B., Sleijfer, D.T. & Stoter, G. (2007). Bleomycin and scuba diving: where is the harm?. Lancet oncol, Vol.8 (11), pp. 954-955.

Krasner, C.N., McMeekin, D.S., Chan, S., Braly, P.S., Renshaw, F.G., Kaye, S., Provencher, D.M., Campos, S., Gore, M.E. & ET-743-INT-II Study Grp, , et al. (2007). A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Brit j cancer, Vol.97 (12), pp. 1618-1624.  show abstract

Baird, R., Planting, A., Reid, A., Kitzen, J., Reade, S., Clarke, P., Welsh, L., Lazaro, L.L., Heras, B.D., Judson, I., et al. (2007). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors. Mol cancer ther, Vol.6 (12), pp. 3381S-3381S.

Benson, C., White, J., De Bono, J., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., et al. (2007). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br j cancer, Vol.96 (1), pp. 29-37.  show abstract

Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N.L., et al. (2007). Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin cancer res, Vol.13 (20), pp. 6187-6194.  show abstract

Forster, M., Kaye, S., Oza, A., Sklenar, I., Johri, A., Cheung, W., Zaknoen, S. & Gore, M. (2007). A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin cancer res, Vol.13 (14), pp. 4178-4184.  show abstract

Kaye, S.B. (2007). Bevacizumab for the treatment of epithelial ovarian cancer: Will this be its finest hour?. J clin oncol, Vol.25 (33), pp. 5150-5152.

Lee, C.P., de Jonge, M.J., O'Donnell, A.E., Schothorst, K.L., Hanwell, J., Chick, J.B., Brooimans, R.A., Adams, L.M., Drolet, D.W., de Bono, J.S., et al. (2006). A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. Clin cancer res, Vol.12 (9), pp. 2841-2848.  show abstract

Reed, N.S., Poole, C.J., Coleman, R., Parkin, D., Graham, J.D., Kaye, S.B., Ostrowski, J., Duncan, I., Paul, J., Hay, A., et al. (2006). A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur j cancer, Vol.42 (2), pp. 179-185.  show abstract

Ratain, M.J., Eisen, T., Stadler, W.M., Flaherty, K.T., Kaye, S.B., Rosner, G.L., Gore, M., Desai, A.A., Patnaik, A., Xiong, H.Q., et al. (2006). Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma. J clin oncol, Vol.24 (16), pp. 2505-2512.  show abstract

Attard, G., Greystoke, A., Kaye, S. & De Bono, J. (2006). Update on tubulin-binding agents. Pathol biol (paris), Vol.54 (2), pp. 72-84.  show abstract

Eisen, T., Ahmad, T., Flaherty, K.T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L.M., et al. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br j cancer, Vol.95 (5), pp. 581-586.  show abstract

Sain, N., Krishnan, B., Ormerod, M.G., De Rienzo, A., Liu, W.M., Kaye, S.B., Workman, P. & Jackman, A.L. (2006). Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol cancer ther, Vol.5 (5), pp. 1197-1208.  show abstract

Larkin, J.M. & Kaye, S.B. (2006). Epothilones in the treatment of cancer. Expert opin inv drug, Vol.15 (6), pp. 691-702.  show abstract

Vidal, L., Yap, T.A., White, C.L., Twigger, K., Hingorani, M., Agrawal, V., Kaye, S.B., Harrington, K.J. & de Bono, J.S. (2006). Reovirus and other oncolytic viruses for the targeted treatment of cancer. Target oncol, Vol.1 (3), pp. 130-150.  show abstract

Agarwal, R. & Kaye, S.B. (2006). Expression profiling and individualisation of treatment for ovarian cancer. Curr opin pharmacol, Vol.6 (4), pp. 345-349.  show abstract

Agarwal, R., Linch, M. & Kaye, S.B. (2006). Novel therapeutic agents in ovarian cancer. Eur j surg oncol, Vol.32 (8), pp. 875-886.  show abstract

Tan, D.S., Agarwal, R. & Kaye, S.B. (2006). Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet oncol, Vol.7 (11), pp. 925-934.  show abstract

Yap, T.A., Vidal, L., Pandha, H., Spicer, J., Digue, L., Coffey, M., Thompson, B., Kaye, S.B., Harrington, K.J. & De-Bono, J.S., et al. (2006). A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer. Ejc suppl, Vol.4 (12), pp. 108-108.

Bhattacharya, B., Krishnan, B., Kaye, S., Ormerod, M., Workman, P. & Jackman, A. (2006). The phosphatidylinositide 3-kinase (PI3-kinase) inhibitor PI103 sensitises some ovarian carcinoma (OC) cell lines to paclitaxel or carboplatin. Ejc suppl, Vol.4 (12), pp. 80-81.

Forster, M., Ormerod, M.G., Agarwal, R., Kaye, S. & Jackman, A.L. (2006). Measuring alpha-folate receptor expression levels on ascites tumour cells may help to identify patients that are more likely to respond to alpha-FR targeted therapy. Ejc suppl, Vol.4 (12), pp. 128-129.

de Bono, J.S., Fong, P.C., Boss, D., Spicer, J., Roelvink, M., Tutt, A., Mortimer, P., O'Connor, M., Schellens, J.H. & Kaye, S.B., et al. (2006). Phase I pharmacolkinetic (PK) and pharmacodynamic (PD) evaluation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advanced tumours. Ejc suppl, Vol.4 (12), pp. 153-153.

Rothermundt, C., Hubner, R., Ahmad, T., Gibbens, I., Keyzor, C., Habeshaw, T., Kaye, S. & Gore, M. (2006). Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. Brit j cancer, Vol.94 (1), pp. 74-78.  show abstract

Vasey, P.A., Atkinson, R., Osborne, R., Parkin, D., Symonds, R., Paul, J., Lewsley, L., Coleman, R., Reed, N.S., Kaye, S., et al. (2006). SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel gemcitabine as first-line chemotherapy for ovarian cancer. Brit j cancer, Vol.94 (1), pp. 62-68.  show abstract

Crawford, S.C., Paul, J., Kaye, S.B., Vasey, P.A., Davis, J.A. & Hay, A. (2006). Aggressive surgery and ovarian cancer - Reply. J clin oncol, Vol.24 (15), pp. 2396-2397.

Crawford, S.C., Paul, J., Kaye, S.B., Vasey, P.A., Davis, J.A. & Hay, A. (2006). Importance of surgical aggressiveness in advanced ovarian cancer - Reply. J clin oncol, Vol.24 (15), pp. 2398-2399.

Agarwal, R. & Kaye, S.B. (2005). Prognostic factors in ovarian cancer: how close are we to a complete picture?. Ann oncol, Vol.16 (1), pp. 4-6.

Blagden, S.P. & Kaye, S.B. (2005). Docetaxel in the management of ovarian cancer. Expert rev anticancer ther, Vol.5 (2), pp. 203-214.  show abstract

Kaye, S.B. (2005). Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2 2 trial. Int j gynecol cancer, Vol.15 Suppl 1, pp. 31-35.  show abstract

Richardson, A. & Kaye, S.B. (2005). Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug resist update, Vol.8 (5), pp. 311-321.  show abstract

Kaye, S.B. (2005). Novel therapeutic approaches: molecular targeted therapy. Ejc suppl, Vol.3 (2), pp. 31-31.

Smit, W.M., Sufliarsky, J., Spanik, S., Wagnerova, M., Kaye, S., Oza, A.M., Gore, M., Williams, K.J., Johri, A. & Huinink, W.W., et al. (2005). Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer. Ejc suppl, Vol.3 (2), pp. 261-262.

Dearnaley, D.P., Fossa, S.D., Kaye, S.B., Cullen, M.H., Harland, S.J., Sokal, M.P., Graham, J.D., Roberts, J.T., Mead, G.M., Williams, M.V., et al. (2005). Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br j cancer, Vol.92 (12), pp. 2107-2113.  show abstract

Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005). Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J clin oncol, Vol.23 (18), pp. 4152-4161.  show abstract

Gifford, G., Paul, J., Vasey, P.A., Kaye, S.B., Brown, R. & Scottish Gynaecological Clinical, (2004). The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin cancer res, Vol.10 (13), pp. 4420-4426.  show abstract

Harries, M., O'Donnell, A., Scurr, M., Reade, S., Cole, C., Judson, I., Greystoke, A., Twelves, C. & Kaye, S. (2004). Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Br j cancer, Vol.91 (9), pp. 1651-1655.  show abstract

Morley, S., MacDonald, G., Kirn, D., Kaye, S., Brown, R. & Soutar, D. (2004). The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin cancer res, Vol.10 (13), pp. 4357-4362.  show abstract

Vidal, L., Garcia-Martin, M., Tan, S., Montes, A., Judson, I., Cuadra, C., Kaye, S., Flores, L., Izquierdo, M.A. & Pardo, B., et al. (2004). Phase I combination study of trabectedin and carboplatin in advanced solid tumors. Ann oncol, Vol.15, pp. 106-106.

Smit, W.M., Honkoop, A.H., Spanik, S., Wagnerova, M., Sufliarsky, J., Oza, A.M., Kaye, S., Pereno, R., Sklenar, I. & Huinink, W.W., et al. (2004). Phase I/II dose-escalation trial of patupilone administered every 3 weeks (q 3 wk) in patients (pts) with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer. Ann oncol, Vol.15, pp. 127-127.

Gore, M., Kaye, S., Oza, A., Keyzor, C., Pyle, L., Pereno, R., Sklenar, I. & Johri, A. (2004). Phase I trial of patupilone plus carboplatin in patients with advanced cancer. Ann oncol, Vol.15, pp. 126-127.

Agarwal, R., Kaye, S., Vasey, P., Paul, J., Gore, M., Wilson, R., Rustin, G., Gabra, H., Guastalla, J.P. & Carty, K., et al. (2004). Eriotinib (E) in combination with docetaxel (D) and carboplatin (C): a phase Ib trial in patients with untreated ovarian, fallopian tube and primary peritoneal cancers. Ann oncol, Vol.15, pp. 127-127.

Vidal, L., Attard, G., Kaye, S. & De Bono, J. (2004). Reversing resistance to targeted therapy. Journal of chemotherapy, Vol.16, pp. 7-12.  show abstract

Hess, V., A'Hern, R., Nasiri, N., King, D.M., Blake, P.R., Barton, D.P., Shepherd, J.H., Ind, T., Bridges, J., Harrington, K., et al. (2004). Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J clin oncol, Vol.22 (6), pp. 1040-1044.  show abstract

Harries, M., Moss, C., Perren, T., Gore, M., Hall, G., Everard, M., A'Hern, R., Gibbens, I., Jenkins, A., Shah, R., et al. (2004). A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br j cancer, Vol.91 (4), pp. 627-632.  show abstract

Vasey, P.A., Jayson, G.C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S.B., et al. (2004). Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J natl cancer inst, Vol.96 (22), pp. 1682-1691.  show abstract

de Jonge, M.J., Kaye, S., Verweij, J., Brock, C., Reade, S., Scurr, M., van Doorn, L., Verheij, C., Loos, W., Brindley, C., et al. (2004). Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. Br j cancer, Vol.91 (8), pp. 1459-1465.  show abstract

LoRusso, P.M., Herbst, R.S., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D., Kaye, S., Gianni, L., Harris, A., et al. (2003). Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin cancer res, Vol.9 (6), pp. 2040-2048.  show abstract

Agarwal, R. & Kaye, S.B. (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat rev cancer, Vol.3 (7), pp. 502-516.  show abstract

Twelves, C., Reck, M., Anthoney, A., Gatzemeier, U. & Kaye, S. (2003). A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies. Cancer chemother pharmacol, Vol.52 (4), pp. 277-281.  show abstract

Baird, R.D. & Kaye, S.B. (2003). Drug resistance reversal--are we getting closer?. Eur j cancer, Vol.39 (17), pp. 2450-2461.  show abstract

Piccart, M.J., Bertelsen, K., Stuart, G., Cassidy, J., Mangioni, C., Simonsen, E., James, K., Kaye, S., Vergote, I., Blom, R., et al. (2003). Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int j gynecol cancer, Vol.13 Suppl 2, pp. 144-148.  show abstract

Kaye, S.B. (2003). Chemotherapy for ovarian cancer: yesterday, today and tomorrow. Brit j cancer, Vol.89, pp. S1-S2.

Kolomainen, D.F., A'Hern, R., Coxon, F.Y., Fisher, C., King, D.M., Blake, P.R., Barton, D.P., Shepherd, J.H., Kaye, S.B. & Gore, M.E., et al. (2003). Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy?. J clin oncol, Vol.21 (16), pp. 3113-3118.  show abstract

Vasey, P.A., McMahon, L., Paul, J., Reed, N. & Kaye, S.B. (2003). A phase II trial of capecitabine (Xeloda (R)) in recurrent ovarian cancer. Brit j cancer, Vol.89 (10), pp. 1843-1848.  show abstract

Kaye, S.B. (2003). Chemotherapy for recurrent ovarian cancer. Lancet, Vol.361 (9375), pp. 2094-2095.

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D.G., Kaye, S.B., Gianni, L., Harris, A., Bjork, T., et al. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J clin oncol, Vol.20 (21), pp. 4292-4302.  show abstract

Swannie, H.C. & Kaye, S.B. (2002). Protein kinase C inhibitors. Curr oncol rep, Vol.4 (1), pp. 37-46.  show abstract

Schellens, J.H., Heinrich, B., Lehnert, M., Gore, M.E., Kaye, S.B., Dombernowsky, P., Paridaens, R., van Oosterom, A.T., Verweij, J., Loos, W.J., et al. (2002). Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Invest new drug, Vol.20 (1), pp. 83-93.  show abstract

Kaye, S. (2002). New paradigms in the treatment of breast and colorectal cancer--an introduction. Eur j cancer, Vol.38 Suppl 2, pp. 1-2.

Kaye, S. (2002). New paradigms in the treatment of breast and colorectal cancer - an introduction. Eur j cancer, Vol.38, pp. S1-S2.

Vasey, P.A., Roché, H., Bisset, D., Terret, C., Vernillet, L., Riva, A., Ramazeilles, C., Azli, N., Kaye, S.B. & Twelves, C.J., et al. (2002). Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Br j cancer, Vol.87 (10), pp. 1072-1078.  show abstract

Kaye, S.B. (2002). Combination chemotherapy for ovarian cancer--lessons not yet learned?. Curr oncol rep, Vol.4 (3), pp. 185-186.

O'Neill, V.J., Kaye, S.B., Reed, N.S., Paul, J., Davis, J.A. & Vasey, P.A. (2002). A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer. Br j cancer, Vol.86 (9), pp. 1385-1390.  show abstract

Kaye, S.B. & Vasey, P.A. (2002). Docetaxel in ovarian cancer: phase III perspectives and future development. Semin oncol, Vol.29 (3 Suppl 12), pp. 22-27.  show abstract

Kaye, S.B. (2002). First-line chemotherapy for ovarian cancer - the controversy continues. Brit j cancer, Vol.87 (8), pp. 813-814.

Moss, C. & Kaye, S.B. (2002). Ovarian cancer: progress and continuing controversies in management. Eur j cancer, Vol.38 (13), pp. 1701-1707.  show abstract

Crown, J., Dieras, V., Kaufmann, M., von Minckwitz, G., Kaye, S., Leonard, R., Marty, M., Misset, J.L., Osterwalder, B. & Piccart, M., et al. (2002). Chemotherapy for metastatic breast cancer - report of a European expert panel. Lancet oncol, Vol.3 (12), pp. 719-727.  show abstract

Vasey, P.A., Shulman, L.N., Campos, S., Davis, J., Gore, M., Johnston, S., Kirn, D.H., O'Neill, V., Siddiqui, N., Seiden, M.V., et al. (2002). Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene - Deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J clin oncol, Vol.20 (6), pp. 1562-1569.  show abstract

Kolomainen, D.F., Larkin, J.M., Badran, M., A'Hern, R.P., King, D.M., Fisher, C., Bridges, J.E., Blake, P.R., Barton, D.P., Shepherd, J.H., et al. (2002). Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J clin oncol, Vol.20 (4), pp. 982-986.  show abstract

Workman, P. & Kaye, S.B. (2002). Translating basic cancer research into new cancer therapeutics. Trends mol med, Vol.8 (4 Suppl), pp. S1-S9.

Propper, D.J., McDonald, A.C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J.P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., et al. (2001). Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J clin oncol, Vol.19 (5), pp. 1485-1492.  show abstract

Kaye, S.B. (2001). New drug development - Its role in reversing drug resistance. Brit j cancer, Vol.85, pp. 5-5.

Harries, M. & Kaye, S.B. (2001). Recent advances in the treatment of epithelial ovarian cancer. Expert opin investig drugs, Vol.10 (9), pp. 1715-1724.  show abstract

Johnston, P.G. & Kaye, S. (2001). Capecitabine: a novel agent for the treatment of solid tumors. Anti-cancer drug, Vol.12 (8), pp. 639-646.  show abstract

Johnston, S.R. & Kaye, S. (2001). Caelyx: treatment for relapsing ovarian cancer. Hosp med, Vol.62 (10), pp. 611-616.  show abstract

Pentheroudakis, G., O'Neill, V.J., Vasey, P. & Kaye, S.B. (2001). Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours - Report of two cases. Support care cancer, Vol.9 (7), pp. 554-557.  show abstract

Kaye, S.B. (2001). Future directions for the management of ovarian cancer. Eur j cancer, Vol.37 Suppl 9, pp. S19-S23.  show abstract

Fizazi, K., Tjulandin, S., Salvioni, R., Germà-Lluch, J.R., Bouzy, J., Ragan, D., Bokemeyer, C., Gerl, A., Fléchon, A., de Bono, J.S., et al. (2001). Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J clin oncol, Vol.19 (10), pp. 2647-2657.  show abstract

Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. & Brown, R. (2000). Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer res, Vol.60 (21), pp. 6039-6044.  show abstract

Mackay, H.J., Cameron, D., Rahilly, M., Mackean, M.J., Paul, J., Kaye, S.B. & Brown, R. (2000). Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J clin oncol, Vol.18 (1), pp. 87-93.  show abstract

Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G.I., Soutar, D.S., Otto, R., Robertson, A.G., Park, O., Gulley, M.L., Heise, C., et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin cancer res, Vol.6 (3), pp. 798-806.  show abstract

Piccart, M.J., Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., Stuart, G., Kaye, S., Vergote, I., Blom, R., et al. (2000). Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J natl cancer inst, Vol.92 (9), pp. 699-708.  show abstract

Gamucci, T., Paridaens, R., Heinrich, B., Schellens, J.H., Pavlidis, N., Verweij, J., Sessa, C., Kaye, S., Roelvink, M., Wanders, J., et al. (2000). Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Ann oncol, Vol.11 (7), pp. 793-797.  show abstract

Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., Gore, M., Ironside, J., MacDougall, R.H., Heise, C., et al. (2000). a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat med, Vol.6 (8), pp. 879-885.  show abstract

Stevenson, J.P., DeMaria, D., Sludden, J., Kaye, S.B., Paz-Ares, L., Grochow, L.B., McDonald, A., Selinger, K., Wissel, P., O'Dwyer, P.J., et al. (1999). Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Ann oncol, Vol.10 (3), pp. 339-344.  show abstract

Fosså, S.D., Stenning, S.P., Gerl, A., Horwich, A., Clark, P.I., Wilkinson, P.M., Jones, W.G., Williams, M.V., Oliver, R.T., Newlands, E.S., et al. (1999). Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br j cancer, Vol.80 (9), pp. 1392-1399.  show abstract

Vasey, P.A., Paul, J., Birt, A., Junor, E.J., Reed, N.S., Symonds, R.P., Atkinson, R., Graham, J., Crawford, S.M., Coleman, R., et al. (1999). Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer Scottish Gynaecological Cancer Trials Group. J clin oncol, Vol.17 (7), pp. 2069-2080.  show abstract

Collette, L., Sylvester, R.J., Stenning, S.P., Fossa, S.D., Mead, G.M., de Wit, R., de Mulder, P.H., Neymark, N., Lallemand, E. & Kaye, S.B., et al. (1999). Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J natl cancer inst, Vol.91 (10), pp. 839-846.  show abstract

Hamilton, T.C., Berek, J.S. & Kaye, S.B. (1999). Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future?. Ann oncol, Vol.10 Suppl 1, pp. 69-73.  show abstract

Kaye, S.B., Mead, G.M., Fossa, S., Cullen, M., deWit, R., Bodrogi, I., van Groeningen, C., Sylvester, R., Collette, L., Stenning, S., et al. (1998). Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J clin oncol, Vol.16 (2), pp. 692-701.  show abstract

de Wit, R., Collette, L., Sylvester, R., de Mulder, P.H., Sleijfer, D.T., ten Bokkel Huinink, W.W., Kaye, S.B., van Oosterom, A.T., Boven, E. & Stoter, G., et al. (1998). Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br j cancer, Vol.78 (10), pp. 1350-1355.  show abstract

Adams, M., Calvert, A.H., Carmichael, J., Clark, P.I., Coleman, R.E., Earl, H.M., Gallagher, C.J., Ganesan, T.S., Gore, M.E., Graham, J.D., et al. (1998). Chemotherapy for ovarian cancer - a consensus statement on standard practice. Brit j cancer, Vol.78 (11), pp. 1404-1406.

Kaye, S.B. (1998). New antimetabolites in cancer chemotherapy and their clinical impact. Br j cancer, Vol.78 Suppl 3, pp. 1-7.  show abstract

Mead, G.M., Stenning, S.P., Cook, P., Fossa, S.D., Horwich, A., Kaye, S.B., Oliver, R.T., deMulder, P.H., deWit, R., Stoter, G., et al. (1997). International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers. J clin oncol, Vol.15 (2), pp. 594-603.  show abstract

Duchesne, G.M., Stenning, S.P., Aass, N., Mead, G.M., Fossa, S.D., Oliver, R.T., Horwich, A., Read, G., Roberts, I.T., Rustin, G., et al. (1997). Radiotherapy after chemotherapy for metastatic seminoma - A diminishing role. Eur j cancer, Vol.33 (6), pp. 829-835.  show abstract

de Wit, R., Stoter, G., Kaye, S.B., Sleijfer, D.T., Jones, W.G., ten Bokkel Huinink, W.W., Rea, L.A., Collette, L. & Sylvester, R. (1997). Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J clin oncol, Vol.15 (5), pp. 1837-1843.  show abstract

Sternberg, C.N., de Mulder, P., Fossa, S., Kaye, S., Roberts, T., Pawinsky, A. & Daamen, S. (1997). Lobaplatin in advanced urothelial tract tumors The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). Ann oncol, Vol.8 (7), pp. 695-696.

Fosså, S.D., Oliver, R.T., Stenning, S.P., Horwich, A., Wilkinson, P., Read, G., Mead, G.M., Roberts, J.T., Rustin, G., Cullen, M.H., et al. (1997). Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur j cancer, Vol.33 (9), pp. 1380-1387.  show abstract

Graham, M.A., Senan, S., Robin Jnr, H., Eckhardt, N., Lendrem, D., Hincks, J., greenslade, D., Rampling, R., Kaye, S.B., von Roemeling, R., et al. (1997). Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose-escalation. Cancer chemother pharmacol, Vol.40, pp. 1-10.

Senan, S., Rampling, R., Graham, M.A., Wilson, P., Robin Jr, H., Eckhardt, N., Lawson, N., McDonald, A., von Roeming, R., Workman, P., et al. (1997). Phase I and pharmacokinetic study of single agent tirapazamine (SR 4233) administered 3-weekly. Clin cancer res, Vol.3, pp. 31-38.

de Wit, R., Sylvester, R., Tsitsa, C., de Mulder, P.H., Sleyfer, D.T., ten Bokkel Huinink, W.W., Kaye, S.B., van Oosterom, A.T., Boven, E., Vermeylen, K., et al. (1997). Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. Br j cancer, Vol.75 (3), pp. 432-435.  show abstract

Cullen, M.H., Stenning, S.P., Parkinson, M.C., Fossa, S.D., Kaye, S.B., Horwich, A.H., Harland, S.J., Williams, M.V. & Jakes, R. (1996). Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A medical research council report. J clin oncol, Vol.14 (4), pp. 1106-1113.  show abstract

Cullen, M.H., Stenning, S.P., Parkinson, M.C., Fossa, S.D., Kaye, S.B., Horwich, A., Harland, S.J., Williams, M.V., Jakes, R. & for the MRC Testicular Tumour Working Party, , et al. (1996). Short course adjuvant chemotherapy in high risk stage 1 non-seminomatous germ cell tumours of the testis: A MRC report. Journal of clinical oncology, Vol.14 (4), pp. 1106-1113.

Piccart, M.J., Gore, M., Ten Bokkel Huinink, W., Van Oosterom, A., Verweij, J., Wanders, J., Franklin, H., Bayssas, M. & Kaye, S. (1995). Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J natl cancer inst, Vol.87 (9), pp. 676-681.  show abstract

de Wit, R., Stoter, G., Sleijfer, D.T., Kaye, S.B., de Mulder, P.H., ten Bokkel Huinink, W.W., Spaander, P.J., de Pauw, M. & Sylvester, R. (1995). Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br j cancer, Vol.71 (6), pp. 1311-1314.  show abstract

Harding, M., Paul, J. & Kaye, S.B. (1995). Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours?. Br j urol, Vol.76 (4), pp. 491-494.  show abstract

Kerr, D.J., Rustin, G.J., Kaye, S.B., Selby, P., Bleehen, N.M., Harper, P. & Brampton, M.H. (1995). Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Br j cancer, Vol.72 (5), pp. 1267-1269.  show abstract

Murphy, D.S., Hoare, S.F., Going, J.J., Mallon, E.E., George, W.D., Kaye, S.B., Brown, R., Black, D.M. & Keith, W.N. (1995). Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J natl cancer inst, Vol.87 (22), pp. 1694-1704.  show abstract

Verweij, J., Wanders, J., Nielsen, A.L., Pavlidis, N., Calabresi, F., ten Bokkel Huinink, W., Bruntsch, U., Piccart, M., Franklin, H. & Kaye, S.B., et al. (1994). Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer EORTC Early Clinical Trials Group. Ann oncol, Vol.5 (4), pp. 375-376.  show abstract

GOEDHALS, L., JORDAAN, J.P., KAYE, S.B., ARMAND, J.P., VEENHOF, C.H., FALKSON, G., SOUKOP, M., SCHNEIDER, M., OBERLING, F., BUI, B.N., et al. (1994). A DOSE-FINDING STUDY OF GRANISETRON, A NOVEL ANTIEMETIC, IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN. Support care cancer, Vol.2 (3), pp. 177-183.  show abstract

CATIMEL, G., VERMORKEN, J.B., CLAVEL, M., DEMULDER, P., JUDSON, I., SESSA, C., PICCART, M., BRUNTSCH, U., VERWEIJ, J., WANDERS, J., et al. (1994). A PHASE-II STUDY OF GEMCITABINE (LY-188011) IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK. Ann oncol, Vol.5 (6), pp. 543-547.  show abstract

Sternberg, C.N., ten Bokkel Huinink, W.W., Smyth, J.F., Bruntsch, V., Dirix, L.Y., Pavlidis, N.A., Franklin, H., Wanders, S., Le Bail, N. & Kaye, S.B., et al. (1994). Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study. Br j cancer, Vol.70 (2), pp. 376-379.  show abstract

Sulkes, A., Smyth, J., Sessa, C., Dirix, L.Y., Vermorken, J.B., Kaye, S., Wanders, J., Franklin, H., LeBail, N. & Verweij, J., et al. (1994). Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial EORTC Early Clinical Trials Group. Br j cancer, Vol.70 (2), pp. 380-383.  show abstract

BLEEHEN, N., CALVERT, A., LEE, S., HARPER, P., KAYE, S., JUDSON, I. & BRAMPTON, M. (1994). A CANCER-RESEARCH CAMPAIGN (CRC) PHASE-II TRIAL OF CB10-277 GIVEN BY 24-HOUR INFUSION FOR MALIGNANT-MELANOMA. Brit j cancer, Vol.70 (4), pp. 775-777.  show abstract

SMYTH, J.F., SMITH, I.E., SESSA, C., SCHOFFSKI, P., WANDERS, J., FRANKLIN, H. & KAYE, S.B. (1994). ACTIVITY OF DOCETAXEL (TAXOTERE) IN SMALL-CELL LUNG-CANCER. Eur j cancer, Vol.30A (8), pp. 1058-1060.  show abstract

de Wit, R., Kaye, S.B., Roberts, J.T., Stoter, G., Scott, J. & Verweij, J. (1993). Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br j cancer, Vol.67 (2), pp. 388-390.  show abstract

AAPRO, M., PIGUET, D., GIGER, K., BAUER, J., HAEFLIGER, J.M., BREMER, K., CALS, L., CATTAN, A., CLAVEL, M., CZYGAN, P., et al. (1993). THE ANTIEMETIC EFFICACY AND SAFETY OF GRANISETRON COMPARED WITH METOCLOPRAMIDE PLUS DEXAMETHASONE IN PATIENTS RECEIVING FRACTIONATED CHEMOTHERAPY OVER 5 DAYS. J cancer res clin, Vol.119 (9), pp. 555-559.  show abstract

Kaye, S.B., Workman, P., Graham, M.A., Cassidy, J. & Jodrell, D. (1993). Pharmacokinetics and early clinical studies of selected new drugs. Cancer surv, Vol.17, pp. 371-396.  show abstract

Stoter, G., Sleijfer, D., Kaye, S.B., Jones, W.G., ten Bokkel Huinink, W.W., de Pauw, M. & Sylvester, R. (1993). Prognostic factors in metastatic non-seminomatous germ cell tumours: an interim analysis of the EORTC GU-Group experience. Eur urol, Vol.23 (1), pp. 202-206.  show abstract

Rankin, E.M., Mill, L., Kaye, S.B., Atkinson, R., Cassidy, L., Cordiner, J., Cruickshank, D., Davis, J., Duncan, I.D. & Fullerton, W., et al. (1992). A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br j cancer, Vol.65 (2), pp. 275-281.  show abstract

KAYE, S.B., BRAMPTON, M., HARPER, P., SMYTH, J., KERR, D.J., GORE, M., GREEN, J.A., GILBY, E., CRAWFORD, S.M. & RUSTIN, G.J., et al. (1992). PHASE-II TRIALS OF FOSQUIDONE, (GR63178A), IN COLORECTAL, RENAL AND NON-SMALL-CELL LUNG-CANCER. Brit j cancer, Vol.65 (4), pp. 624-625.  show abstract

KAYE, S.B., WANDERS, J., CLAVEL, M., VERWEIJ, J., PICCART, M.J., SMYTH, J.F., HUININK, W.W., WAGENER, D.J., JUDSON, I.R. & CAVALLI, F., et al. (1992). PHASE-II TRIALS OF FOSQUIDONE (GR63178A) IN CARCINOMA OF THE BREAST, HEAD AND NECK, OVARY AND MELANOMA. Ann oncol, Vol.3 (5), pp. 406-408.  show abstract

Stoter, G., Akdas, A., Fosså, S.D., Kaye, S.B., van Groeningen, C.J., Renard, J. & van Glabbeke, M. (1992). High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study EORTC Genito-Urinary Tract Cancer Co-operative Group EORTC Early Clinical Trials Group. Ann oncol, Vol.3 (7), pp. 577-578.  show abstract

Jones, A.L., Hill, A.S., Soukop, M., Hutcheon, A.W., Cassidy, J., Kaye, S.B., Sikora, K., Carney, D.N. & Cunningham, D. (1991). Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet, Vol.338 (8765), pp. 483-487.  show abstract

Bindemann, S., Soukop, M. & Kaye, S.B. (1991). Randomised controlled study of relaxation training. Eur j cancer, Vol.27 (2), pp. 170-174.  show abstract

Jansen, R.L., Sylvester, R., Sleyfer, D.T., ten Bokkel Huinink, W.W., Kaye, S.B., Jones, W.G., Keizer, J., van Oosterom, A.T., Meyer, S. & Vendrik, C.P., et al. (1991). Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group). Eur j cancer, Vol.27 (6), pp. 695-698.  show abstract

KERR, D.J., LEWIS, C., ONEIL, B., LAWSON, N., BLACKIE, R.G., NEWELL, D.R., BOXALL, F., COX, J., RANKIN, E.M. & KAYE, S.B., et al. (1990). THE MYELOTOXICITY OF CARBOPLATIN IS INFLUENCED BY THE TIME OF ITS ADMINISTRATION. Hematol oncol, Vol.8 (1), pp. 59-63.

Geller, N.L., Scher, H.I., Parmar, M.K., Dalesio, O. & Kaye, S. (1990). Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer?. Semin oncol, Vol.17 (5), pp. 628-634.

Stoter, G., Bosl, G.J., Droz, J.P., Fossa, S.D., Freedman, L.S., Geller, N.L., Horwich, A., Jones, W.G., Kaye, S.B. & Mead, G.M., et al. (1990). Prognostic factors in metastatic germ cell tumors. Prog clin biol res, Vol.357, pp. 313-319.

Cummings, J., Double, J.A., Bibby, M.C., Farmer, P., Evans, S., Kerr, D.J., Kaye, S.B. & Smyth, J.F. (1989). Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer res, Vol.49 (13), pp. 3587-3593.  show abstract

CASSIDY, J., LEWIS, C., SETANOIANS, A., ADAMS, L., KERR, D.J., CALVERT, A.H., BROWN, G.W., PATEMAN, A.J., RANKIN, E.M. & KAYE, S.B., et al. (1989). PHASE-1 TRIAL OF GR63178A. Brit j cancer, Vol.60 (3), pp. 457-457.

Boyle, P., Soukop, M., Scully, C., Robertson, A.G., Burns, H.J., Gillis, C.R. & Kaye, S.B. (1988). Improving prognosis of Hodgkin's disease in Scotland. Eur j cancer clin oncol, Vol.24 (2), pp. 229-234.  show abstract

Graham, J., Harding, M., Mill, L., Kerr, D.J., Rankin, E., Calman, K.C. & Kaye, S.B. (1988). Results of treatment of non seminomatous germ cell tumours; 122 consecutive cases in the West of Scotland, 1981-1985. Br j cancer, Vol.57 (2), pp. 182-185.  show abstract

Calvert, A.H., Horwich, A., Newlands, E.S., Begent, R., Rustin, G.J., Kaye, S.B., Harris, A.L., Williams, C.J. & Slevin, M.L. (1988). Carboplatin or cisplatin?. Lancet, Vol.2 (8610), pp. 577-578.

CANTWELL, B., MACAULAY, V., HARRIS, A., KAYE, S., SMITH, I., MILSTED, R. & CALVERT, A. (1988). PHASE-II STUDY OF THE ANTIFOLATE N-10-PROPARGYL-5,8-DIDEAZAFOLIC ACID (CB-3717) IN ADVANCED BREAST-CANCER. Eur j cancer clin on, Vol.24 (4), pp. 733-736.

Deans, G., Bennett-Emslie, G.B., Weir, J., Smith, D.C. & Kaye, S.B. (1988). Cancer support groups--who joins and why?. Br j cancer, Vol.58 (5), pp. 670-674.  show abstract

Cummings, J., Kerr, D.J., Kaye, S.B. & Smyth, J.F. (1988). Optimisation of a reversed-phase high-performance liquid chromatographic method for the determination of flavone acetic acid and its major human metabolites in plasma and urine. J chromatogr, Vol.431 (1), pp. 77-85.  show abstract

Boyle, P., Kaye, S.B. & Robertson, A.G. (1987). Changes in testicular cancer in Scotland. Eur j cancer clin oncol, Vol.23 (6), pp. 827-830.  show abstract

STUARTHARRIS, R.C., HARPER, P.G., PARSONS, C.A., KAYE, S.B., MOONEY, C.A., GOWING, N.F. & WILTSHAW, E. (1983). HIGH-DOSE ALKYLATION THERAPY USING IFOSFAMIDE INFUSION WITH MESNA IN THE TREATMENT OF ADULT ADVANCED SOFT-TISSUE SARCOMA. Cancer chemoth pharm, Vol.11 (2), pp. 69-72.

STUARTHARRIS, R., HARPER, P.G., KAYE, S.B. & WILTSHAW, E. (1983). HIGH-DOSE IFOSFAMIDE BY INFUSION WITH MESNA IN ADVANCED SOFT-TISSUE SARCOMA. Cancer treat rev, Vol.10, pp. 163-164.

FITZHARRIS, B.M., KAYE, S.B., SAVERYMUTTU, S., NEWLANDS, E.S., BARRETT, A., PECKHAM, M.J. & MCELWAIN, T.J. (1980). VP16-213 AS A SINGLE AGENT IN ADVANCED TESTICULAR-TUMORS. Eur j cancer, Vol.16 (9), pp. 1193-1197.

KAYE, S., JUTTNER, C., SMITH, I., BARRETT, A., AUSTIN, D., PECKHAM, M. & MCELWAIN, T. (1979). 3 YEARS EXPERIENCE WITH CH1VPP (A COMBINATION OF DRUGS OF LOW TOXICITY) FOR THE TREATMENT OF HODGKINS-DISEASE. Brit j cancer, Vol.39 (2), pp. 168-174.

KAYE, S., BAGSHAWE, K., MCELWAIN, T. & PECKHAM, M. (1979). BRAIN METASTASES IN MALIGNANT TERATOMA - REVIEW OF 4 YEARS EXPERIENCE AND AN ASSESSMENT OF THE ROLE OF TUMOR-MARKERS. Brit j cancer, Vol.39 (3), pp. 217-223.

Benson, C., Kaye, S., Workman, P., Garrett, M. & De Bono, J.S. Clinical anticancer drug development: targeting the cyclin dependent kinases. Br j cancer 2005, (92), pp. 7-12.

Legge, F., Eaton, D., Molife, L.R., Ferrandina, G., Judson, I.R., De Bono, J.S. & Kaye, S.B. Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center. Gynecol oncol. 2007 mar;104(3) epub 2006 oct 24., , pp. 551-556.

Linardopoulos, S., dolly, S., gurden, M., drosopoulos, K., clarke, P., bono, J., kaye, S. & workman, P. RNAi screen reveals synthetic lethality between Cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. British journal of cancer, .

Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B., Amnon, A., Bell-McGuinn, K.M., Chen, L.M., Friedlander, M., et al. A Phase II, open-label, randomized, multicentre study to compre the efficacy and safety of olaparib,a poly(ADP-ribose) polymerase (PARP) inhibitor, and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J clin oncol, .

Lee, C.P., de Jonge, M.J., O'Donnell, A., Schothorst, K., Hanwell, J., Chick, J., Adams, L., Drolet, D.W., De Bono, J.S., Kaye, S.B., et al. A Phase I study of a new nucleoside analogue, OSI-7836, using two administered schedules in patients with advanced solid malignancy. Clin cancer res. 2006, Vol.9 (12), pp. 2841-2848.

Benson, C., White, J., De Bono, J.S., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Frenz, L., Rose, F., Walton, M., et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202;R-Roscovitine), administered twice daily for 7-days every 21 days. Br j cancer. 2007, Vol.1 (96), pp. 29-37.

van der Graaf, W. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in Phase I clinical trials. European journal of cancer, .


Book Chapters

Yap, T.A., Kaye, S.B., Ashworth, A. & Tutt, A. (2011). Tumour specific synthetic lethality: targeting BRCA dysfunction in ovarian cancer. In Kaye, S.B., Brown, R., Gabra, H. & Gore, M. (Eds.), Emerging Therapeutic Targets in Ovarian Cancer. (pp. 109-33). New York, Springer Science.

Carden, C.P., Kipps, E. & Kaye, S.B. (2011). Prognostic factors in epithelial ovarian cancer. In Poveda, A. (Ed.), 100 Key Questions on Ovarian Cancer. (pp. 23-12). Barcelona, Permanyer Publications.

Nicum, S. & Kaye, S.B. (2011). Epithelial ovarian cancer. In Ajithkumar, T., Barrett, A., Hatcher, H. & Cook, N. (Eds.), Oxford Desk Reference: Oncology. (pp. 346-354). New York, Oxford University Press.

Yap, T.A., Sarker, D., Kaye, S.B. & de Bono, J.S. (2009). Functional imaging: clinicalapplications in molecular targeted therapy. In Husband, J.E. & Reznek, R.H. (Eds.), Imaging in Oncology. 3rd ed (pp. 1388-17). Informa Healthcare.

Collins, I., Molife, R., Kaye, S.B. & Workman, P. (2007). Rational drug design of small molecule anticancer agents: Preclinical discovery. In Alison, M.R. (Ed.), The Cancer Handbook. 2nd ed. (pp. 1199-1215). Chichester, UK, John Wiley & Sons Ltd.

Molife, R., Collins, I., Kaye, S.B. & Workman, P. (2007). Rational drug design of small molecule anticancer agents: Early clinical development. In Alison, M.R. (Ed.), Cancer Handbook. 2nd ed. (pp. 1216-1241). Chichester, UK, John Wiley & Sons Ltd.

Kaye, S.B. & Workman, P. (2002). Signal transduction pathway signalling. Cancer Handbook. (pp. 1497-1505). Nature Publishing Group.

Drew, Y., Yap, T.A. & Kaye, S.B. The future of PARP inhibitors in the treatment of cancer. In Kehoe, S., Edmondson, R.J., Gore, M. & McNeish, I.A. (Eds.), Gynaeacological Cancers: Biology and Therapeutics. (p. 83). RCOG Press.

Nicum, S. & Kaye, S.B. Epithelial ovarian cancer. In Ajithkumar, T., Cook, N., Hatcher, H., Barrett, A. & Aapro, M. (Eds.), Oxford Desk Reference: Oncology. Oxford University Press.


Conferences

Glasspool, R., Lewsley, L.-., Daniele, G., Cook, A.D., Yanaihara, N., Tinker, A., Kristensen, G., Ottevanger, P., Aravantinos, G., Boere, I.A., et al. (2018). Progression free survival as a surrogate endpoint for overall survival in first-line therapy of advanced ovarian cancer: A Gynecologic Cancer InterGroup (GCIG) individual patient-level meta-analysis, BRITISH JOURNAL OF CANCER, Vol.119 (11), pp.47-48.

Ledermann, J.A., Embleton, A.C., Perren, T., Jayson, G.C., Rustin, G.J., Kaye, S.B., Hirte, H.W., Oza, A.M., Vaughan, M.M., Friedlander, M., et al. (2017). Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer., Journal of Clinical Oncology, Vol.35 (15_suppl), p.5506.

Matulonis, U.A., Penson, R.T., Domchek, S.M., Kaufman, B., Audeh, M.W., Kaye, S.B., Molife, L.R., Mann, H., Robertson, J. & Coleman, R.L., et al. (2015). Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis, Gynecologic Oncology, Vol.137, pp.8-9.

Boussios, S., Glaessgen, D., Okines, A., Lalondrelle, S., Taylor, A., McLachlan, J., Gore, M., Kaye, S. & Banerjee, S. (2015). 2767 Second line systemic treatment options for recurrent/advanced cervical cancer - The Royal Marsden experience, European Journal of Cancer, Vol.51, p.S553.

Banerjee, S., Ledermann, J., Matulonis, U., Molife, L.R., Friedlander, M., Fielding, A., Robertson, J.D., Spencer, S., McMurtry, E. & Kaye, S., et al. (2015). 2759 Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib, European Journal of Cancer, Vol.51, p.S550.

Lheureux, S., Ledermann, J.A., Runswick, S., Hodgson, D.R., Timms, K., Lanchbury, J.S., Kaye, S.B., Gourley, C., Bowtell, D., Kohn, E.C., et al. (2015). Genomic characterization of long-term responders to olaparib., Journal of Clinical Oncology, Vol.33 (15_suppl), p.5566.

Rafii, S., Gourley, C., Ang, J.E., Kumar, R., Geuna, E., Rye, T., Ashcroft, L., Powell, B., Shapira-Frommer, R., Friedlander, M., et al. (2015). What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?, Journal of Clinical Oncology, Vol.33 (15_suppl), p.5546.

Migali, C., Lima, J.P., George, A., Pepa, C.D., Kaye, S.B., Gore, M.E. & Banerjee, S. (2014). 902POVARIAN CARCINOSARCOMA MANAGEMENT: A RETROSPECTIVE ANALYSIS OF THE ROYAL MARSDEN EXPERIENCE, Annals of Oncology, Vol.25 (suppl_4), p.iv314.

Hook, J., Stenning, S.P., Brenton, J., Kaye, S.B., McNeish, I.A., Naik, R., Perren, T., Petrie, J., Farrelly, L., Dean, A.P., et al. (2014). ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer., Journal of Clinical Oncology, Vol.32 (15_suppl), p.TPS5611.

Dedes, K.J., Wilkerson, P., Wetterskog, D., Lambros, M.B., Natrajan, R., Tan, D.S., Campion-Flora, A., Rodrigues, D.N., Gauthier, A., Daley, F., et al. (2012). PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance, MODERN PATHOLOGY, Vol.25, p.265A.

Dedes, K.J., Wilkerson, P., Wetterskog, D., Lambros, M.B., Natrajan, R., Tan, D.S., Campion-Flora, A., Rodrigues, D.N., Gauthier, A., Daley, F., et al. (2012). PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance, LABORATORY INVESTIGATION, Vol.92, p.265A.

Kaye, S.B., Siu, L.L., Jassem, J., Medioni, J., Soetekouw, P.M., Slater, S., Rudin, C.M., Schwartz, G.K., De Jonge, M., O'Dwyer, P., et al. (2012). BRIVANIB (B) IN ADVANCED OVARIAN CANCER (OC): SUBSET RESULTS OF A PHASE 2 RANDOMIZED DISCONTINUATION TRIAL (RDT), ANNALS OF ONCOLOGY, Vol.23, p.319.

Kaye, S.B. (2012). TARGETING DNA REPAIR DEFICIENCY IN OVARIAN AND ENDOMETRIAL CANCERS, ANNALS OF ONCOLOGY, Vol.23, p.40.

George, A., Tunariu, N., Wilkinson, N., Gupta, S., Gore, M.E., Kaye, S.B. & Banerjee, S. (2012). EFFICACY OF PLATINUM PLUS GEMCITABINE (G) IN PLATINUM-RESISTANT (R) COMPARED TO PLATINUM-SENSITIVE (S) OVARIAN CANCER: THE ROYAL MARSDEN EXPERIENCE, ANNALS OF ONCOLOGY, Vol.23, p.320.

Miller, R., Brough, R., Bajrami, I., Kaye, S., Banerjee, S., Lord, C. & Ashworth, A. (2012). Functional Profiling of Clear Cell Ovarian Cancer, EUROPEAN JOURNAL OF CANCER, Vol.48, p.33.

Miller, R., Brough, R., Bajrami, I., Kaye, S.B., Lord, C.J. & Ashworth, A. (2012). Functional profiling of clear cell ovarian cancer., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Molife, L.R., Mateo, J., McGoldrick, T., Krebs, M., Drew, Y., Banerjee, S.N., Nicum, S., Ranson, M., Rustin, G.J., Sessa, C., et al. (2012). Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations, JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Gupta, A., Moreno, V., Dean, E.J., Drew, Y., Nicum, S., Ranson, M., Plummer, R., Swaisland, H., Burke, W., McCormack, P., et al. (2012). Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Ploquin, A., Olmos, D., Lacombe, D.A., A'Hern, R., Duhamel, A., Twelves, C., Marsoni, S., Morales, R., Soria, J.-., Verweij, J., et al. (2012). Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin level., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Velasco, A.P., Monk, B., Kaye, S., Vermorken, J., Nieto, A., Gomez, J., Park, Y., Parekh, T., Colombo, N. & Vergote, I., et al. (2011). Prediction of Overall Survival (OS) Adjusted by Continuous Platinum-free Interval (PFI) at Fixed Timepoints in Patients With Recurrent Ovarian Cancer (ROC) - Results From OVA-301, Presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, SWEDEN. EUROPEAN JOURNAL OF CANCER, Vol.47, pp.S536-S537.

Kaye, S.B., Fehrenbacher, L., Holloway, R., Horowitz, N., Karlan, B., Amit, A., Slomovitz, B., Chang, I., Yauch, R.L. & Reddy, J.C., et al. (2010). A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF HEDGEHOG (HH) PATHWAY INHIBITOR GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN 2(ND) OR 3(RD) COMPLETE REMISSION (CR), Presented at 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, ITALY. ANNALS OF ONCOLOGY, Vol.21, p.11.

Olmos, D., Marsoni, S., Tabernero, J., Gomez-Roca, C., Verweij, J., Voest, E., Schoffski, P., Penel, N., Schellens, J.H. & Kaye, S., et al. (2010). A European multi-institutional study of prognostic factors in cancer patients (pts) treated within Phase I Ph I)oncology trials, Presented at 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, ITALY. Annals of Oncology, Vol.21, p.162.

Kaye, S., Kaufman, B., Lubinski, J., Matulonis, U., Gourley, C., Karlan, B., Taylor, D., Wickens, M. & Carmichael, J. (2010). PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS, Presented at 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, ITALY. ANNALS OF ONCOLOGY, Vol.21, p.304.

Colombo, N., Schwartz, P.E., Bamias, A., Bae, D.S., Rzepka-Gorska, I., Kaye, S.B., Conte, P.F., Weber, D., Li, J. & Kutarska, E., et al. (2010). RESULTS OF A RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF PATUPILONE (P) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN TAXANE/PLATINUM REFRACTORY/RESISTANT PATIENTS WITH RECURRENT OVARIAN, FALLOPIAN, OR PERITONEAL CANCER, Presented at 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, ITALY. ANNALS OF ONCOLOGY, Vol.21, p.11.

Aamdal, S., Boven, E., De Vries, E., Lauraine, E.P., Freyer, G., Jones, R., Prahladan, M., Emeribe, U. & Kaye, S. (2010). PHASE I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SARACATINIB (AZD0530) PLUS CARBOPLATIN (C) AND/OR PACLITAXEL (P) IN PATIENTS WITH SOLID TUMOURS, Presented at 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, ITALY. ANNALS OF ONCOLOGY, Vol.21, pp.171-172.

Singh, S., Bunker, C.B., Kaye, S., Tristem, M., Gore, M.E. & McClure, M.O. (2009). Expression of human endogenous retrovirus k (HERV-K) mRNA and production of putative viral particles by melanoma cell lines, Presented at 69th Annual Meeting of the Society-of-Investigative-Dermatology, Montreal, CANADA. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol.129, p.S136.

Singh, S., Kaye, S., Francis, N.D., Peston, D., Gore, M.E., McClure, M.O. & Bunker, C.B. (2009). Quantification of human endogenous retrovirus k (HERV-K) expression in primary melanoma, normal skin and benign naevi, Presented at 69th Annual Meeting of the Society-of-Investigative-Dermatology, Montreal, CANADA. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol.129, p.S137.

Tan, D., Brunetto, A., Yap, T., Frentzas, S. & Kaye, S. (2009). BRCA1 positive ovarian cancer (OC): a predisposition to therapeutic selectivity, Presented at Educational Cancer Convention (ECCLU), Lugano, SWITZERLAND. Annals of Oncology, Vol.20, p.22.

Brunetto, A., Tan, D., Yap, T., Olmos, D. & Kaye, S. (2009). COMPLICATIONS OF ANTI-ANGIOGENIC THERAPY, Presented at Educational Cancer Convention (ECCLU), Lugano, SWITZERLAND. ANNALS OF ONCOLOGY, Vol.20, p.24.

Kaye, S. (2009). Emerging new targets in ovarian cancer, Presented at 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, GERMANY. EJC SUPPLEMENTS, Vol.7 (2), p.50.

Olmos, D., Brunetto, A., Ang, J., Tan, D., Sandhu, S., Kristeleit, R., Lolkelma, M., Forster, M., Molife, R. & Kaye, S., et al. (2009). Retrospective analysis of unplanned hospital admissions: an early surrogate indicator of patient (pt) attrition in phase-I trials, Presented at 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, GERMANY. EJC SUPPLEMENTS, Vol.7 (2), pp.137-138.

Poveda, A., Kaye, S., Herzog, T., Ghatage, P., Meerpohl, H., Ngan, H., Emerich, J., Tercero, J.C., Ricci, D. & Monk, B., et al. (2009). Correlation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs Trabectedin (T) plus PLD in the ET743-OVA-301 clinical trial, Presented at 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, GERMANY. EJC SUPPLEMENTS, Vol.7 (2), pp.451-452.

Baird, R., Clare, J., St Rose, S., Manu, C., Linch, M., Stavridi, F., Hook, J., Barbachano, Y., Gore, M. & Kaye, S., et al. (2009). Weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer - Royal Marsden Hospital experience, Presented at 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, GERMANY. EJC SUPPLEMENTS, Vol.7 (2), pp.464-465.

Bidzinski, M., Poveda, A., Vermorken, J., Kaye, S., Makhson, A., Jagiello-Gruszfeld, A., Poole, C., Gomez, J., Parekh, T. & Monk, B., et al. (2009). Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer, Presented at 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, GERMANY. EJC SUPPLEMENTS, Vol.7 (2), p.468.

Krasner, C.N., Poveda, A., Herzog, T., Vermorken, J., Monk, B., Zintl, P., Li, J., Su, Y., Dhawan, R. & Kaye, S., et al. (2009). Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone, Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Ledermann, J.A., Rustin, G.J., Hackshaw, A., Kaye, S.B., Jayson, G., Gabra, H., James, L.E., Bell, S. & Temple, G. (2009). A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC), Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Montes, A., Sandhu, S.K., Rothermundt, C., Coombes, I., A'Hern, R., Keyzor, C., Thomas, A., Kaye, S. & Gore, M. (2009). Phase I feasibility study of carboplatin plus capecitabine followed by maintenance capecitabine in patients (pts) with recurrent platinum-sensitive epithelial ovarian cancer (EOC), Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Kaye, S.B., Vasey, P., Rustin, G., Pledge, S., Williams, C., Gabra, H., Skailes, G., Lamont, A., Lewsley, L., Paul, J., et al. (2009). Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4), Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Poveda, A., Kaye, S.B., McCormack, R.T., Wang, S., Ricci, D., Broderick, E., Parekh, T., Lebedinsky, C., Tecero, J.C. & Monk, B.J., et al. (2009). Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD, Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Glasspool, R.M., Gore, M., Rustin, G., McNeish, I., Wilson, R., Pledge, S., Paul, J., Mackean, M., Halford, S., Kaye, S., et al. (2009). Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer, Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Carden, C.P., Frentzas, S., Langham, M., Casamayor, I., Stephens, A.W., Poondru, S., Wheaton, J., Lippman, S.M., Kaye, S.B. & Kim, E.S., et al. (2009). Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors, Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Monk, B.J., Herzog, T., Kaye, S., Krasner, C.N., Vermorken, J., Muggia, F., Pujade-Lourraine, E., Renshaw, F.G., Lebedinsky, C. & Poveda, A., et al. (2008). A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC), Presented at 33rd European-Society-for-Medical-Oncology Congress, Stockholm, SWEDEN. ANNALS OF ONCOLOGY, Vol.19, p.2.

Appleton, K., Mackay, H.J., Judson, I., Plumb, J.A., McCormick, C., Strathdee, G., Lee, C., Barrett, S., Reade, S., Jadayel, D., et al. (2007). Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors, Presented at 17th EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA. JOURNAL OF CLINICAL ONCOLOGY, Vol.25 (29), pp.4603-4609.

Martin, L.A., Head, J.E., Pancholi, S., Salter, J., Quin, E., Detre, S., Kaye, S., Howes, A., Dowsett, M. & Johnston, S.R., et al. (2007). The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell-cycle progression in-vitro and in-vivo, Presented at 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. BREAST CANCER RESEARCH AND TREATMENT, Vol.106, p.S203.

Salazar, R., Vidal, L., Majem, M., Barlow, C., Pardo, B., Nadarajah, T., Cuadra, C., de Miguel, B., Lebedinsky, C. & Kaye, S., et al. (2006). Clinical and pharmacokinetic phase I combination study of trabectedin (T) and carboplatin (C) in patients with advanced solid tumors, Presented at 30th Congress of the European-Society-for-Medical-Oncology, Istanbul, TURKEY. ANNALS OF ONCOLOGY, Vol.17, p.140.

Smit, W.M., Sufliarsky, J., Spanik, S., Wagnerova, M., Kaye, S., Oza, A.M., Gore, M., Williams, K., Johri, A. & Huinink, W.W., et al. (2005). Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer., Presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.468S.

Shah, R.N., Everard, M., Keyzor, C., Hall, K., A'Hern, R., Blake, P., Gore, M.E. & Kaye, S.B. (2005). A sequential doublet chemotherapy regimen in patients (pts) with advanced endometrial adenocarcinoma (EC) and gynecological mixed mullerian tumors (MMT). Maintaining activity with tolerability?, Presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.474S.

Crawford, S.C., Vasey, P.A., Paul, J., Hay, A., Davis, J.A. & Kaye, S.B. (2005). Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial, Presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (34), pp.8802-8811.

Blohmer, J., Gore, M., Kuemmel, S., Verheijen, R.H., Kimmig, R., Massuger, L.F., Du Bois, A., Smit, W.M., Kaye, S. & Deubelbeiss, C., et al. (2005). Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer., Presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.174S.

Crawford, S.C., Vasey, P.A., Paul, J., Hay, A., Davis, J.A., Kaye, S.B. & Scottish Gynaecological Canc Trial, (2005). Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial., Presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.455S.

McMeekin, D.S., Krasner, C., Chan, S., Braly, P., Kaye, S., Provencher, D., Trifan, O.C., Michiels, B. & Gore, M. (2005). Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma., Presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.457S.

Gore, M., Kaye, S., Oza, A., Keyzor, C., Pyle, L., Pereno, R., Sklenar, I., Zaknoen, S. & Johri, A. (2005). Phase I trial of patupilone plus carboplatin in patients with advanced cancer., Presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.476S.

Krishnan, B., Ormerod, M.G., Kaye, S.B. & Jackman, A.L. (2005). Sensitisation of trail-resistant ovarian cancer cell line SKOV-3 to carboplatin by HGS-ETR1 and HGS-ETR2, Presented at 3rd International Symposium on Targeted Anticancer Therapies, Amsterdam, NETHERLANDS. ANNALS OF ONCOLOGY, Vol.16, pp.43-44.

Barrett, S.V., Lee, C.P., Appleton, K.J., Reade, S., Jadayel, D., Bellenger, K., Mackay, L.M., Twelves, C.J., Kaye, S.B., Judson, I.R., et al. (2005). Phase I trial of the DNA hypomethylating agent 5-aza-2 ' deoxycytidine (decitabine) in combination with carboplatin both given 4-weekly by intravenous injection in patients with advanced solid tumours., Presented at AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA. CLINICAL CANCER RESEARCH, Vol.11 (24), p.9058S.

Brown, R., Appleton, K., Plumb, J.A., McCormick, C., Lee, C., Barrett, S., Tang, A., Schaetzlein, A., Kaye, S.B., Judson, I., et al. (2005). Pharmacodynamic effects in patients treated with 6 hour infusion of the demethylating agent 5-aza-2 ' deoxycytidine (decitabine)., Presented at AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA. CLINICAL CANCER RESEARCH, Vol.11 (24), pp.9071S-9072S.

Dark, G.G., Calvert, A.H., Grimshaw, R., Poole, C., Swenerton, K., Kaye, S., Coleman, R., Jayson, G., Le, T., Ellard, S., et al. (2005). Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the National Cancer Institute of Canada Clinical Trials Group, Presented at 38th Annual Meeting of the American-Society-of-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (9), pp.1859-1866.

Kaye, S.B. (2004). Proteasome inhibition: potential benefits in the treatment of cancer, Presented at Symposium on Proteasome Inhibition as A Major Advance in Oncology, Copenhagen, DENMARK. EJC SUPPLEMENTS, Vol.2 (6), pp.7-11.

Shah, R.N., Everard, M., Keyzor, C., Hall, K., Ahern, R., Gore, M.E. & Kaye, S.B. (2004). Carboplatin plus doxorubicin (CD) and carboplatin plus paclitaxel (CP) given as a sequential doublet in endometrial cancer (EC) and mixed mesodermal tumours (MMT)., Presented at British Cancer Research Meeting 2004, Manchester, ENGLAND. BRITISH JOURNAL OF CANCER, Vol.91, p.S43.

Hubner, R., Ahmad, T., Rigg, A., Kaye, S., Gibbens, I., Keyzor, C., Prouse, A. & Gore, M. (2004). Epirubicin-carboplatin-capecitabine (ECarboX) in relapsed ovarian cancer: A phase I/II trial, Presented at British Cancer Research Meeting 2004, Manchester, ENGLAND. BRITISH JOURNAL OF CANCER, Vol.91, p.S42.

Smit, W.M., Honkoop, A.H., Spanik, S., Wagnerova, M., Huinink, W.W., Oza, A.M., Kaye, S.B., Mull, R., Pereno, R. & Sklenar, I., et al. (2004). A phase I/II dose-escalation trial of EP0906 every 3 weeks in patients with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer., Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.474S.

Lee, C., Appleton, K., Plumb, J., Kaye, S., Cruickshank, C., Twelves, C., Vasey, P., Judson, I., Brown, R. & Mackay, H., et al. (2004). A phase I trial of the DNA-hypomethylating agent 5-Aza-2 '-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid turnouts., Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.128S.

Ratain, M.J., Flaherty, K.T., Stadler, W.M., O'Dwyer, P., Kaye, S., Xiong, H., Patnaik, A., Gore, M., Lee, R.J. & Eisen, T., et al. (2004). Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT), Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.382S.

Vasey, P., Kaye, S., Paul, J., Rustin, G., Wilson, R., Guastalla, J.P., Pujade-Lauraine, E., Gore, M., Gabra, H., Carty, K., et al. (2004). A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers., Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.453S.

Krasner, C.N., McMeekin, S., Chan, S., Braly, P., Kaye, S., Provencher, D., Klecz, J., Michiels, B., Van de Velde, H.V. & Gore, M., et al. (2004). A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma., Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.460S.

Hubner, R., Ahmad, T., Rigg, A., Kaye, S., Gibbens, I., Keyzor, C., Prouse, A. & Gore, M. (2004). Epirubicin-carboplatin-capecitabine (ECarboX) in relapsed ovarian cancer: A phase I/II trial., Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.476S.

Ratain, M.J., Stadler, W., Smith, M., Kindler, H., O'Dwyer, P., Flaherty, K.T., Kaye, S., Xiong, H., Eisen, T., Patnaik, A., et al. (2003). Phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer., Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, BOSTON, MASSACHUSETTS. CLINICAL CANCER RESEARCH, Vol.9 (16), pp.6265S-6266S.

Kaye, S., Gershensen, D., Hung, M.C. & Seiden, M. (2003). Discussion: Molecular therapeutics and pharmacogenomics, Presented at 8th International Forum on Ovarian Cancer, STOCKHOLM, SWEDEN. GYNECOLOGIC ONCOLOGY, Vol.88 (1), pp.S93-S96.

Perren, T., Gore, M., Hall, G., Everard, M., A'Hern, R., Cole, C., Gibbens, I., Jenkins, A. & Kaye, S. (2003). Carboplatin (C) followed by sequential weekly paclitaxel (T) and gemcitabine (G) as first-line treatment for ovarian cancer., Presented at British Cancer Research Meeting 2003, BOURNEMOUTH, ENGLAND. BRITISH JOURNAL OF CANCER, Vol.88, p.S58.

Kaye, S.B. (2003). What are the clinical trial priorities of the future?, Presented at 12th European Cancer Conference (ECCO 12), COPENHAGEN, DENMARK. EJC SUPPLEMENTS, Vol.1 (6), pp.147-154.

Kaye, S. (2003). First-line chemotherapy, Presented at Symposium on Key Advances in the Clinical Management of Ovarian Cancer, ROYAL SOC MED, LONDON, ENGLAND. KEY ADVANCES IN THE CLINICAL MANAGEMENT OF OVARIAN CANCER, , pp.33-37.

Kaye, S., Oza, A., Gore, M., Huinink, W., Smit, W., Gibbon, D., Miller, W., Mull, R., Chitale, K. & Rothermel, J., et al. (2002). Preliminary results from a Phase II trial of EPO906 patients with advanced refractory ovarian cancer, Presented at 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, FRANKFURT, GERMANY. EUROPEAN JOURNAL OF CANCER, Vol.38, p.S43.

Kaye, S.B. (2002). Drug Resistance reversal - are we getting closer?, Presented at 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, FRANKFURT, GERMANY. EUROPEAN JOURNAL OF CANCER, Vol.38, p.S3.

Johnston, S.R., Head, J.E., Valenti, M.R., Detre, S., Brunton, L.A., De Rienzo, A., Howes, A.J., End, D., Kaye, S. & Dowsett, M., et al. (2002). Endocrine therapy combined with the farnesyl transferase inhibitor (FTI) R115777 produces enhanced tumor growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in-vivo., Presented at 25th San Antonio Breast Cancer Symposium, SAN ANTONIO, TEXAS. BREAST CANCER RESEARCH AND TREATMENT, Vol.76, p.S71.

Kaye, S.B. & Scottish Gynaecological Canc Trial, (2001). The integration of docetaxel into first-line chemotherapy for ovarian cancer, Presented at 3rd International Sumposium on Advanced Ovarian Cancer: Optimal Therapy Update, VALENCIA, SPAIN. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol.11, pp.31-33.

Kaye, S.B. (2001). Chemotherapy for testicular cancer: present standards and future advances, Presented at VIth Congress on Progress and Controversies in Oncological Urology (PACIOU VI), ROTTERDAM, NETHERLANDS. RENAL, BLADDER, PROSTATE AND TESTICULAR CANCER: AN UPDATE, , pp.29-33.